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Abstract
Aminoglycoside nucleotidyltransferase(2″)-Ia is one of the most important
aminoglycoside-modifying enzymes. Because of the difficulties in isolating this enzyme
with a high level of purity, very little work has been reported for this enzyme. A
procedure for obtaining this enzyme with a purity level of greater than 95% from
inclusion bodies was developed. The optimal conditions for isolating ANT(2″) were
solubilizing the inclusion bodies in 8 M urea followed by direct dilution of the enzyme
into 0.1 M Tris-HCl pH 8.5, 0.2 M KCl, 0.4 M L-arginine and 5 mM reduced glutathione
at 4°C. The determination of an effective method of obtaining this enzyme allowed for
characterization by thermodynamic and kinetic methods. Fluorescence spectroscopy
titrations showed that ANT(2″) binds MgATP much tighter than free ATP and electron
paramagnetic resonance (EPR) experiments showed that the enzyme binds a second
divalent cation in addition to the one in the MgATP complex. Isothermal titration
calorimetry (ITC) was used to show that binding of metal–nucleotide increases the
affinity for the aminoglycoside substrate for all but one aminoglycoside. The binding of
aminoglycosides to ANT(2″) occurs with a favorable negative enthalpy and unfavorable
negative entropy. Molecular determinants of substrate specificity for aminoglycosides
were also determined. An amino group at the 2′ position is preferred over a 2′-hydroxyl in
terms of greater catalytic efficiency (kcat/Km) and tighter binding. The same preference is
observed at the 6′ position where an amino group rather than a hydroxyl at that position
leads to tighter binding. The 1 position on the deoxystreptamine ring is also shown to be
important in terms of binding and catalysis.
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Part I. Introduction

1

Aminoglycoside antibiotics
Aminoglycoside-aminocyclitol antibiotics, commonly referred to as aminoglycosides,
are broad-spectrum antibiotics that are effective against Gram-positive and Gramnegative bacteria. The first aminoglycoside used was streptomycin which was discovered
in 1944 in a search to find antibiotics capable of treating Gram-negative infections (1).
The introduction of streptomycin was followed by the discovery of several more antibacterials produced by organisms from the genuses Streptomyces and Micromonospora.
Later semi-synthetic aminoglycosides were produced by the modification of the
naturally-occurring compounds. These semi-synthetic aminoglycosides were designed to
thwart resistance mechanisms and to reduce harmful side effects associated with
aminoglycosides.
The common feature of these molecules is an aminocyclitol ring. For most
aminoglycosides this ring is 2-deoxystreptamine. One notable exception is streptomycin
which has a streptidine ring. The 2-deoxystreptamine containing aminoglycosides can be
further grouped into the 4,5-disubstituted and 4,6-disubstituted aminoglycosides. The
nomenclature refers to the position of the amino sugar substituents linked to the 2deoxystreptamine ring (Figure 1). Three methods of naming the rings are present in the
literature. The conventions for referring to these rings are as follows: The amino sugar at
position 4 is ring I, ring A or the primed ring. The deoxystreptamine ring is ring II ring B
or the unprimed ring. The amino sugar at position 4 or 5 is ring III, ring C or the double
primed ring. For aminoglycosides with more than three rings the additional rings
connected to ring C are rings D and E which can also be referred to as rings IV and V or
as the triple and quadruple primed rings.
2

Figure 1. A 4,5-disubstituted aminoglycoside (neomycin B) is shown on the left and a
4,6-disubstituted aminoglycoside (kanamycin B) is shown on the right.

3

Aminoglycosides bind to the tRNA (A site) binding site of the 16S rRNA of the 30S
ribosomal subunit of prokaryotic organisms leading to an increase in translational errors
(2, 3). The initial entry of aminoglycosides into the cell is not well understood. Since
anaerobic bacteria are unaffected by aminoglycoside antibiotics the entry is thought to be
dependent on the electrical potential generated by the electron transport system (4).
Further evidence supporting this theory is that inhibitors of electron transport also prevent
the uptake of aminoglycosides (5, 6). This initial entry of a small amount of
aminoglycosides causes mistranslation of proteins leading to a more permeable
membrane (7). This increased permeability allows for the increased influx of
aminoglycosides, leading to more mistranslated protein which leads to death of the
organism (8, 9).
Aminoglycoside antibiotics continue to be useful in the treatment of several Gramnegative organisms. Specifically, enterobacteriaceae and Pseudomonas aeruginosa
infections acquired in a clinical setting are usually treated with an aminoglycoside.
Aminoglycosides are also often a component of multidrug treatment for difficult to treat
infections (10, 11). An example of this strategy is the use of streptomycin in a multidrug
treatment regimen to treat Mycobacterium tuberculosis which has acquired resistance to
the newer treatment methods (12). Aminoglycosides also continue to be used in
externally-applied antibacterials such as eye infection treatments.
Although these compounds are still widely used, the use of aminoglycosides has
decreased because of two factors. First, the side effects associated with these drugs
incude damage to the ear and kidney. These side effects may be caused by
aminoglycosides binding to human rRNA and affecting protein production.
4

Aminoglycosides have been shown to bind eukaryotic rRNA. However this affinity is
tenfold lower than the affinity for prokaryotic rRNA (13, 14). Also aminoglycosides have
been shown to inhibit ornithine decarboxylase and activate phospholipase C which are
important signaling components in the cell (15, 16). Both of these factors may contribute
to the side effects caused by these antibiotics. Second, resistance mechanisms have
developed as a response to treatment with aminoglycosides. These mechanisms include
drug efflux pumps and modified target ribosomal RNA (17, 18). However the most
prevalent cause of resistance to aminoglycosides is the presence of enzymes which
covalently modify aminoglycosides (19, 20).

Aminoglycoside-modifying enzymes
Over fifty enzymes have been identified which cause resistance to aminoglycoside
antibiotics (21). These enzymes include N-acetyltransferases (AACs), Ophosphotransferases (APHs), and O-nucleotidyltransferases (ANTs). The covalent
modification of aminoglycosides by these enzymes greatly reduces the ability of the
antibiotic to bind the rRNA (22). Aminoglycoside acetyltransferases transfer the acetyl
group from acetyl CoA to an amino group on aminoglycosides. The AACs are members
of the Gcn5-related N-acetyltransferases (GNAT) superfamily of enzymes. This
superfamily includes histone acetyltransferases and serotonin N-acetyltransferases. The
APHs are closely related to kinases including eukaryotic protein kinases.
Aminoglycoside phosphotransferases transfer the γ-phosphate from ATP to a hydroxyl on
an aminoglycoside. Aminoglycoside nucleotidyltransferases transfer the adenyl group
from ATP to a hydroxyl on the aminoglycoside. The ANTs are members of the
5

nucleotidyltransferase superfamily. This superfamily includes DNA polymerases and
RNA polymerases.
At least one crystal structure has been published for each of the three groups of
aminoglycoside-modifying enzymes (23-25). In each case the overall fold of the
aminoglycoside-modifying enzyme more closely resembles other members of its
superfamily than enzyme structures from other classes of aminoglycoside-modifying
enzymes. The same comparison holds true for primary sequences. The sequences of
different classes of aminoglycoside-modifying enzymes are not closely related. These
relationships suggest that aminoglycoside-modifying enzymes are an example of
convergent evolution. These enzymes may have evolved from proteins which carry out
different functions in the organism to provide antibiotic resistance to the bacteria.
The genes for most of these enzymes are carried on R-plasmids. These plasmids often
carry more than one resistance enzyme and can be transferred between species. The
prevalence of individual resistance enzymes is dependent on the usage patterns of
aminoglycosides in a given area (26).
Each type of modifying enzyme contains several members each of which is specific
for modifying primarily at one position on aminoglycoside molecules. Each enzyme is
capable of several different aminoglycosides. Also, each aminoglycoside can be
modified by several different enzymes (Figure 2).
The site of modification for each enzyme is indicated in parenthesis, a roman numeral
follows to indicate the resistance profile conferred by the enzyme and finally a lower case
letter is used for different primary sequences with the same resistance pattern.

6

Figure 2. A single aminoglycoside can be modified by several different enzymes. The
sites of modification of kanamycin B are indicated with arrows and the modifying
enzymes for each position are indicated.

7

Aminoglycoside nucleotidyltransferase (2″)-Ia
One of the most important aminoglycoside modifying enzymes (AGMEs) is
aminoglycoside nucleotidyltransferase (2″) (ANT(2″)). This enzyme was first identified
in a clinical isolate of Klebsiella pneumoniae in 1971 (27). By 1985 ANT(2″) was the
most often detected aminoglycoside modifying enzyme in resistant clinical isolates in
North America and had been found in other continents in patients who had never traveled
outside their native country (28, 29). Despite the medical importance of this enzyme, very
little biochemical work has been done with this protein. This protein is difficult to isolate
in large quantities with a high level of purity (30, 31). Also this enzyme is relatively
unstable and has a low degree of solubility. ANT(2″) catalyzes the adenylation of
aminoglycosides which contain a hydroxyl group at the 2″ position (Figure 1). The
reaction is shown in figure 3.
Early work with ANT(2″) focused on correlation of in vitro substrate specificity
determined by kinetic assays with in vivo resistance determined by minimum inhibitory
concentration (MIC) testing. Data from these studies were often contradictory, probably
due to the use of different assays to monitor activity and the varying levels of purity of
enzyme preparations used in the in vitro studies (30-33). However one observation that
was consistent in these studies was substrate inhibition at increasing aminoglycoside
concentrations. Later, an extensive kinetic study quantified this substrate inhibition (34).
This work also showed that the reaction followed an ordered Theorell-Chance
mechanism with the metal-nucleotide binding first, followed by the aminoglycoside
substrate (35). These studies were conducted with a mixture of two enzyme variants and

8

Figure 3. The reaction catalyzed by ANT(2″) is shown with tobramycin as
the aminoglycoside substrate.
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the amino acid sequence of the enzyme was not known. Even though the primary
sequence was not known, an analysis of the amino acid composition was reported (36).
The enzyme used by Gates and Northrop (34, 35) has a different composition than the
one used in the present study. However there is no evidence that the enzyme used in the
present study does not follow the mechanism originally proposed by Gates and Northrop.
The amino acid sequence of ANT(2") (figure 4) does not show significant homology
to any other aminoglycoside nucleotidyltransferase (less than 5% identity and less than
15% similarity based on BLAST searches and use of CLUSTALW to align the
sequences (37, 38)). The acetyl- and phophotransferases are even less similar to
ANT(2"). Thus the few well-characterized other AGMEs (19, 39) cannot be reliably used
to predict characteristics of this enzyme. Also this enzyme is one of only four of the over
fifty known aminoglycoside modifying enzymes to modify primarily at positions on ring
C of aminoglycosides (Figure 1) (21). Most AGMEs modify positions on the A or B ring.
A project was initiated to gain insight into ANT(2″) because of its clinical importance,
its unique properties and the lack of biochemical data on this enzyme available in the
scientific literature. This project resulted in the development of a method to isolate large
quantities of this enzyme with a high degree of purity (Part II, (40)). This project also
produced the first thermodynamic characterization of ANT(2″) including binding
affinities of substrates and cofactors (Part III,(41)). Also determinants of specificity for
ANT(2″) were established by comparing the affinities for different aminoglycoside
antibiotics (Part IV). Finally the role of cysteine residues in this enzyme was investigated
and one cysteine was found to be critical for enzyme activity (Part V).
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MACYDCFFVQ SMPRASKQQA RYAVGRCLML
WSSNDVTQQG SRPKTKLGRM DTTQVTLIHK
ILAAADERNL PLWIGGGWAI DARLGRVTRK
HDDIDLTFPG ERRGELEAIV EMLGGRVMEE
LDYGFLAEIG DELLDCEPAW WADEAYEIAE
APQGSCPEAA EGVIAGRPVR CNSWEAIIWD
YFYYADEVPP VDWPTKHIES YRLACTSLGA
EKVEVLRAAF RSRYAA
Figure 4. The amino acid sequence of ANT(2″)-Ia is shown.
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Abstract
Aminoglycoside nucleotidyltransferase(2″)-Ia (ANT(2″)) confers resistance to
pathogenic bacteria against several aminoglycoside antibiotics including gentamicin,
kanamycin and tobramycin. The gene for this aminoglycoside-modifying enzyme has
been cloned from a clinical isolate of Pseudomonas aeruginosa. This gene was inserted
into an overexpression vector, the vector was then transformed into Escherichia coli
BL21(DE3) and the protein has been isolated in the form of inclusion bodies. Optimal
refolding conditions have been determined to be direct dilution of solubilized inclusion
bodies into 0.1 M Tris-HCl pH 8.5, 0.2 M KCl, 0.4 M L-arginine and 5 mM reduced
glutathione at 4°C. The refolded enzyme is monomeric in solution and has similar kinetic
properties and substrate selectivity to the enzyme isolated in soluble form.

Introduction
Aminoglycoside antibiotics bind to the 16S ribosomal RNA of prokaryotes increasing
the frequency of translational errors. These errors decrease the integrity of the bacterial
cell wall allowing the influx of more aminoglycoside molecules to interact with the
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rRNA leading to the death of the organism (1-4). ANT(2″) catalyzes the covalent
attachment of adenosine monophosphate (AMP) to the 2″ position of 4,6-disubstituted
aminoglycoside antibiotics (Figure1). The overall reaction is

MgATP + 2″-hydroxyaminoglycoside → MgPPi + AMP-2″-aminoglycoside

The modified aminoglycoside is no longer able to bind effectively to the ribosomal RNA.
Thus bacteria which possess the gene for this enzyme are resistant to 4,6-disuubstituted
aminoglycosides which contain a hydroxyl group at the 2″ position.
Over fifty enzymes have been identified which covalently modify aminoglycosides
(5). These include acetyltransferases and phosphotransferases as well as two other
nucleotidyltransferases, ANT(3″) and ANT(4′,4″). Of all the aminoglycoside-modifying
enzymes ANT(2″) is the most prevalent in North America (5,6). Although several of
these enzymes have been well characterized (7-9), very little data exists for ANT(2″) due
to the difficulties in purification of the soluble enzyme, the relative instability of the
enzyme and the low yield of soluble enzyme from culture (10-12).
Overexpression of ANT(2″) even at lower temperatures and minimal levels of IPTG
leads to less than 5% of the enzyme present in the soluble fraction of the cell lysate
(Figure 2A). The remaining >95% is present in the insoluble fraction in the form of
inclusion bodies. Since the refolding of proteins isolated from inclusion bodies vary
among individual proteins, a test to find the optimal conditions for refolding ANT(2″) in
active form was devised based on commonly used refolding protocols (13-15).
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Tobramycin

Kanamycin A

Sisomicin

Figure 1. Aminoglycoside substrates of ANT(2″) used in this work. The hydroxyl group
which is the site of adenylation is in bold.
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Soluble

Insoluble

MW Std.

A.

ANT(2″)

B.

45 kDa

← ANT(2″)

31 kDa

Figure 2. SDS-PAGE of ANT(2″)-Ia showing majority of the enzyme in insoluble
fraction after cell lysis (A) and purity after refolding (B).
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Materials and Methods
Materials. E. coli BL21(DE3) and pET 22b(+) were purchased from Novagen
(Madison, WI). Trizma® base, reduced glutathione (GSH), oxidized glutathione (GSSG),
L-arginine, kanamycin A, tobramycin and sisomicin were purchased from Sigma (St.
Louis, MO). All restriction enzymes and potassium chloride were purchased from Fisher
Scientific (Fair Lawn, NJ). Isopropylthiogalactopyranoside (IPTG) and dithiothreitol
(DTT) were purchased from Inalco Pharmaceuticals (Milan, Italy). Inorganic
pyrophosphatase was purchased from Roche Diagnostics (Indianapolis, IN).
Cloning and Expression. The gene for ANT(2″)-Ia was cloned as described previously
from the R-plasmid of a clinical isolate of Pseudomonas aeruginosa kindly provided by
Dr. Karen Shaw at Schlering-Plough (16). The gene was inserted between the NdeI and
BamHI sites in the multiple cloning region of pET 22b(+). The plasmid was transformed
into E. coli BL21(DE3). The cells containing the recombinant plasmid were grown at
37°C on an LB plate containing 50 µg/ml ampicillin and 20 µg/ml tobramycin. A single
colony was inoculated into 10 ml LB medium containing 50 µg/ml ampicillin. After
overnight growth this culture was transferred to 1L of LB containing 50 µg/ml ampicillin.
Cells were grown with vigorous shaking at 37°C. When the culture reached an OD600 of
0.4, IPTG was added at a final concentration of 0.5 mM to induce overexpression. After
induction, the cells were grown an additional 6 h and harvested by centrifugation at
6000g for 15 min at 4°C. The pellet was washed with STE (10 mM Tris-HCl pH 8.0, 0.1
M NaCl and 1 mM EDTA) and the centrifugation was repeated. The cells were
resuspended in 50 mM Tris-HCl, 0.1 M NaCl and 1 mM EDTA and lysed by two passes
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through a French press at 18,000 lb/in2. The soluble and insoluble fractions of the cell
lysate were separated by centrifugation at 12,000g for 15 min at 4°C.
Inclusion body preparation. The insoluble fraction of the cell lysate containing the
ANT(2″) inclusion bodies was washed two times in 10 mM Tris-HCl pH 8.0, 1 mM
EDTA, 10 mM DTT and 0.5% Triton X-100. The wash was repeated two additional
times with the same buffer lacking Triton X-100. After each wash the inclusion bodies
were pelleted by centrifugation at 20,000g for 20 min at 4°C. The inclusion bodies were
solubilized by incubation in 8 M urea, 0.1 M Tris-HCl pH 8.0 and 10 mM DTT at a
concentration of 25-35 mg/ml for 1 h at room temperature. The remaining insoluble
material was removed by centrifugation at 30,000g for 30 min.
Determination of optimal refolding conditions. Seventy-two sets of refolding
conditions were tested. A matrix was devised varying temperature, pH, salt
concentration, anti-aggregation agents and reducing agents. Each refolding buffer was
prepared and used at both 4°C and 25°C. Each buffer contained 0.1 M Tris-HCl at pH
8.0, 8.5 or 9.0. The concentrations of KCl used to test the effect of salt concentration on
refolding were 0 M, 0.05 M and 0.2 M. Either 0.4 M L-arginine and 2% glycine or 10%
glycerol and 5% ethylene glycol were used to reduce aggregation during refolding. Also,
either 5 mM DTT or 10 mM reduced glutathione and 1 mM oxidized glutathione were
used to determine the optimal reducing agent or reduction–oxidation pair. Initial screens
also tested 2-mercaptoethanol as a reducing agent, but in all cases the results were
inferior to those obtained using DTT or glutathione.
To 10 ml of each refolding buffer 0.25 mg of inclusion bodies solubilized in 8 M urea,
0.1 M Tris-HCl pH 8.0 and 10 mM DTT were added. After 8 h the solution was
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concentrated to 2 ml under nitrogen in a stirred cell ultrafiltration unit with a modified
polyethersulfone membrane (Pall Gelman). Each set of conditions was evaluated based
on protein recovery and enzymatic activity. The samples showing highest recovery and
activity were subjected to analytical gel filtration to determine the relative amount of
monomer and dimer compared to higher order oligomers.
Protein concentration was determined by the absorption at 280 nm and confirmed by
the method of Bradford using BSA as the standard (17).
Activity assay. The activity assay utilized was described previously (16). The assay is
based on the conversion of inorganic pyrophosphate to two molecules of inorganic
phosphate by inorganic pyrophosphatase. The amount of inorganic phosphate is
determined by the method of Ames (18). The assay mixture included 50 mM TAPS pH
8.5, 50 mM KCl, 5 mM MgCl2 , 0.5 mM ATP, 0.01 mM – 0.2 mM aminoglycoside and
2.0 units of inorganic pyrophosphatase except in the Vmax and Km determinations. In
these assays ATP was varied from 0.1 mM - 2.0 mM and MgCl2 was varied accordingly
to maintain a constant free magnesium concentration. Kanamycin A was varied from
0.01- 0.15 mM in the Km and Vmax determinations. One unit of activity represents the
production of 1.0 µmole of product per minute.
Analytical gel filtration. Aliquots of 50 µl containing refolded ANT(2″) were analyzed
on a Zorbax GF-250 4.6 × 250 mm gel filtration column (Agilent) attached to an Agilent
1100 series HPLC system equipped with a UV/vis detector. The mobile phase used was
0.1 M Tris-HCl pH 8.2, 0.1 M KCl and 1.0 mM DTT.
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Large scale refolding. For larger scale refolding experiments 5 mg of solubilized
inclusion bodies were diluted into 250 ml of refolding buffer. The solution was kept at
4°C for 12-16 h and then concentrated to 3-4 ml by ultrafiltration.

Results
Cloning and expression. In earlier work with ANT(2″), two forms of the enzyme were
isolated from bacteria harboring the original plasmid taken from clinical isolates. These
proteins had apparent molecular weights of 35,000 Da and 29,000 Da (10). Analysis of
the DNA sequence suggested the two forms could be due to two start sites, one coding
for a polypeptide of 249 amino acids and the other coding for a polypeptide of 226 amino
acids (19). Both forms were cloned and expressed. Each form was found almost entirely
in the insoluble portion of the cell lysate. Both the 226 and 249 amino acid versions of
ANT(2″) refolded optimally under similar conditions. However, the shorter version
consistently had higher levels of expression, a greater percentage recovery from refolding
and higher specific activity (Table 1). Therefore the data in the remainder of this
manuscript will refer to the 226 amino acid version of this protein unless otherwise noted.
Determination of optimal refolding conditions. The best results were obtained when
the refolding buffer consisted of 0.1 M Tris-HCl pH 8.5, 0.2 M KCl, 0.4 M L-arginine,
2% glycine, 10 mM glutathione (reduced) and 1 mM glutathione (oxidized). The use of
this refolding buffer resulted in ≥ 96% recovery of protein and a specific activity of 0.23
units mg-1. The complete tables of results for the thirty-six conditions tested at both 4°C
and 25°C are shown in tables 3 and 4 in the appendix.
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Table 1:Expression and purification of ANT(2″) from two different start sites
Purity After
Percentage of
Percent
Refolding
Activity
Total
Yielda
recoveryb
from
(mg)
Protein
units/mg
(%)
Inclusion
Expressed
Bodies
First start
site 249
15-20%
47-55
60-64
0.17
≥ 85%
amino
acids
Second
start site
25-30%
74-91
68-77
0.23
≥ 95%
226 amino
acids
a
Milligrams of refolded protein per liter culture (1 liter = 7.1-7.6 g wet weight cells)
b
Percent of total ANT(2″) recovered after refolding
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Several trends were apparent in testing the refolding buffers. For most conditions
refolding at 4°C and 25°C yielded similar percent recovery of ANT(2″). However the
specific activity was almost always greater when the enzyme was refolded at 4°C.
Refolding at pH 8.0 or 8.5 was always better than refolding at pH 9.0. Although the use
of 10% glycerol and 5% ethylene glycol resulted in soluble, active protein , ANT(2″)
refolded in buffers containing this set of anti-aggregation agents had a much greater
tendency to form tetramers and higher order oligomers than protein refolded in buffers
containing arginine and glycine. The results using DTT and glutathione were similar in
most cases. DTT can be substituted for glutathione with only a slight decrease in protein
recovery and similar specific activity.
After establishing the optimal set of refolding conditions in small scale experiments, a
larger scale refolding was undertaken. Five mg of ANT(2″) was diluted into 250 ml of
buffer. After concentration to 4 ml, 73% of the original protein was recovered with a
specific activity of 0.20 units mg-1. The diminished recovery is due to increased losses
incurred during concentration of a larger volume of protein solution.
After establishing this base set of conditions, studies were conducted to determine the
optimal concentration of each refolding buffer component. Varying the glycine
concentration from 0-10% (w/v) had no significant effect on refolding efficiency (data
not shown). Therefore glycine was omitted from the refolding buffer. At arginine
concentrations above 0.4 M a decrease in specific activity was observed (Figure 3A).
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Figure 3. Effect of concentration of arginine and reducing agents on refolding. Activity
under the base set of refolding conditions (0.23 units mg-1) was used as 100 % activity.
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Therefore the arginine concentration was kept at 0.4 M throughout. The omission of a
reducing agent in the refolding buffer resulted in a significant decrease in protein
recovery with no loss of specific activity. However, increasing the concentration of DTT
above 5 mM or reduced glutathione above 10 mM led to a decrease in activity (Fig 3B).
The use of oxidized glutathione had no significant effect on recovery or activity so it was
omitted from the refolding buffer. The detergent CHAPS, and cosolvents polyethylene
glycol and magnesium salts were also tested. None of these additives improved the
recovery or activity of the enzyme (data not shown). After these changes the refolding
buffer consisted of 0.1 M Tris-HCl pH 8.5, 0.2 M KCl, 0.4 M arginine and 5 mM
glutathione (reduced) prepared and used at 4°C. Under these conditions the purity of the
refolded ANT(2″) is greater than 93% (Fig 1B) and primarily monomeric when refolded
in this buffer (Figure 4).
Activity and substrate specificity. The substrate rate profile of ANT(2″) refolded from
inclusion bodies is in agreement with previous studies using the enzyme purified in
soluble form (Table 2). The only group to do a comprehensive kinetic study on ANT(2″)
used a slightly different form of the enzyme (22). However the values for Km and Vmax
obtained using ANT(2″) refolded from inclusion bodies are similar to the values reported
for enzyme isolated in soluble form. Gates and Northrup reported a Km of 126.0 µM and
Vmax of 5.3 units mg-1 for kanamycin A (21). ANT(2″) refolded from inclusion bodies
using the methods described in this paper has a Km of 155 µM and Vmax of 3.0 units mg-1
using kanamycin A as the aminoglycoside substrate.
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A280

Time (min)
Figure 4. Gel filtration profile of refolded ANT(2″) isolated primarily as a monomer.
Elution times of molecular weight standards BSA (67000 Da) and carbonic anhydrase
(29000 Da) are indicated.
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Table 2: Substrate specificity of ANT(2″)
Refolded from
Bongaerts
Devaud et Gates and
Inclusion Bodies
and
al(20)
Northrup(21)b
Molenijk(12)
Sisomicin
166
292
284
99
a
Tobramycin
100
100
100
100
Kanamycin A
63
56
NT
52
a
Rate using tobramycin for each study set to 100 for comparative purposes
b
ANT(2″) used in this study is a different isoform of the enzyme
NT: not tested

Smith and
Smith(10)
NT
100
51
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Discussion
Earlier protocols for obtaining ANT(2″) from soluble fractions required several
chromatographic steps. The time required to isolate the protein in this manner reduces the
time available to perform experiments with this unstable enzyme. Also since this enzyme
is known to bind cellulose and dextran, significant losses occur when columns containing
these materials are employed (12,22). Previous work with ANT(2″) isolated from
inclusion bodies resulted in an active oligomeric form of the enzyme which retained most
of the properties of the monomeric species (16). However since ANT(2″) isolated from
pathogenic bacteria has been shown to be a monomer , working with an oligomeric
species is not ideal. The specific activity of the monomer is almost twice the activity
observed utilizing the oligomeric species. Also, although the aminoglycoside substrates
adopt similar conformations in the active sites of different aminoglycoside-modifying
enzymes, (23) ANT(2″) has a low degree of sequence homology with these other
enzymes (24). So the more well-studied aminoglycoside-modifying enzymes are not a
reliable model for the structural and activity-related aspects of this enzyme. Refolding the
enzyme from inclusion bodies using the methods described herein will facilitate more
detailed structural and biochemical studies with ANT(2″).
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Table 3: Refolding of ANT (2″) at 4°C
Condition testeda
pH 8.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG

% Recovery

Specific Activity
(units mg-1)

48

0.10

60

0.15

56

0.16

60

0.086

80

0.14

72

0.18

60

0.11
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Table 3 cont.
Condition testeda
pH 8.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.5
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.5
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT

% Recovery

Specific Activity
(units mg-1)

48

0.10

60

0.15

56

0.16

60

0.086

80

0.14

72

0.18

60

0.11
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Table 3 cont.
Condition testeda
pH 8.5
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.5
0 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.5
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.5
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.5
0 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.5
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.5
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG

% Recovery

Specific Activity
(units mg-1)

56

0.17

60

0.082

88

0.16

76

0.20

56

0.092

96

0.18

> 98

0.23

41

Table 3 cont.
Condition testeda
pH 8.5
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.5
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.5
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 9.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 9.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 9.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 9.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT

% Recovery

Specific Activity
(units mg-1)

56

0.17

60

0.082

88

0.16

76

0.20

56

0.092

96

0.18

> 98

0.23
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Table 3 cont.
Condition testeda
pH 9.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 9.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 9.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 9.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 9.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 9.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 9.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG

% Recovery

Specific Activity
(units mg-1)

36

0.10

44

0.13

52

0.11

64

0.13

68

0.13

32

0.057

40

0.062
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Table 3 cont.
Condition testeda
pH 9.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
a
All buffers contain 0.1 M Tris-HCl

% Recovery

Specific Activity
(units mg-1)

40

0.064
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Table 4: Refolding of ANT (2″) at 25°C
Condition testeda
pH 8.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG

% Recovery

Specific Activity
(units mg-1)

56

0.094

60

0.14

60

0.14

60

0.068

76

0.092

72

0.11

64

0.091
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Table 4 cont.
Condition testeda
pH 8.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.5
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.5
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT

% Recovery

Specific Activity
(units mg-1)

80

0.13

92

0.17

48

0.074

64

0.12

80

0.13

52

0.080

56

0.10
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Table 4 cont.
Condition testeda
pH 8.5
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 8.5
0 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.5
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.5
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 8.5
0 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.5
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 8.5
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG

% Recovery

Specific Activity
(units mg-1)

56

0.10

56

0.11

88

0.14

56

0.17

36

0.070

80

0.16

76

0.20
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Table 4 cont.
Condition testeda
pH 8.5
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.5
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 8.5
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 9.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 9.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 9.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM DTT
pH 9.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT

% Recovery

Specific Activity
(units mg-1)

52

0.12

60

0.15

72

0.086

40

0.074

44

0.13

60

0.057

32

0.038
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Table 4 cont.
Condition testeda
pH 9.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 9.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM DTT
pH 9.0
0 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 9.0
0.05 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 9.0
0.2 M KCl
0.4 M Arginine
2% Glycine
5 mM GSH, 1 mM GSSG
pH 9.0
0 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
pH 9.0
0.05 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG

% Recovery

Specific Activity
(units mg-1)

40

0.060

44

0.057

60

0.063

68

0.094

68

0.089

44

0.061

64

0.072
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Table 4 cont.
Condition testeda
pH 9.0
0.2 M KCl
10% Glycerol
5% Ethylene Glycol
5 mM GSH, 1 mM GSSG
a
All buffers contain 0.1 M Tris-HCl

% Recovery

Specific Activity
(units mg-1)

60

0.070
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Part III: Enzyme–Substrate Interactions with an Antibiotic Resistance Enzyme:
Aminoglycoside Nucleotidyltransferase(2″)-Ia Characterized by Kinetic and
Thermodynamic Methods
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This section is a slightly revised version of a manuscript by Edward Wright and Engin
H. Serpersu published in Biochemistry in 2005.
Wright, E. and Serpersu, E.H. (2005) Enzyme–Substrate Interactions with an Antibiotic
Resistance Enzyme: Aminoglycoside Nucleotidyltransferase(2″)-Ia Characterized by
Kinetic and Thermodynamic Methods, Biochemistry 44, 11581-11591.
My contributions to this manuscript include performing all experimental procedures,
conducting all data collection and data analysis, writing the initial draft of the manuscript
and participating in all subsequent drafts including the final accepted manuscript.

Abstract
Aminoglycoside nucleotidyltransferase(2″)-Ia is one of the most often detected
enzymes in aminoglycoside-resistant bacteria. Despite its prevalence, little biochemical
and biophysical work has been reported for this enzyme. In the current study, substrate
specificity and temperature dependence of kcat are determined by kinetic assays.
Dissociation constants and thermodynamic properties of enzyme–substrate complexes are
determined by isothermal titration calorimetry, electron paramagnetic resonance and
fluorescence spectroscopy. Kinetic studies show that aminoglycosides with 2′-NH2 are
better substrates (higher kcat/Km) than ones with 2′-OH when magnesium (II) is used as
the catalytically-required divalent cation. The activity is reduced ten-fold for substrates
with 2′-NH2 when manganese (II) replaces magnesium as the required metal. However,
kanamycin A, which has a 2′-OH shows a much smaller decrease in activity when
manganese substitutes for magnesium as the divalent cation. Temperature dependence
studies show the activation energy of catalysis to be 19.2 kcal/mol and the temperature
optimum between 30 and 32°C. The binding of the aminoglycoside substrate tobramycin
to the enzyme occurs with a favorable enthalpy which compensates for a large entropic
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penalty to yield a negative ΔG value for the complex formation. Enthalpy of binding is
less exothermic in the presence of metal–nucleotide. However, due to the more favorable
entropy, a more favorable ΔG is observed for the formation of the enzyme–metal–
nucleotide:aminoglycoside complex. Tobramycin binds to ANT(2″) with a dissociation
constant of 0.6 μM, which is further reduced by three-fold when metal–nucleotide is
present. Binding of ATP to the enzyme is determined to be very weak in the absence of a
divalent cation, and becomes two orders of magnitude tighter when magnesium or
manganese is present. Binding studies also show that, in addition to binding to the
enzyme in the form of metal–nucleotide complex, a second catalytically required metal
binds to an additional site on the enzyme.

Introduction
Bacterial resistance to treatment with aminoglycoside antibiotics can result from
several factors including drug efflux pumps and modified target ribosomal RNA (1, 2).
However the most prevalent cause of resistance to aminoglycosides is the presence of
enzymes which covalently modify aminoglycosides (3, 4). These covalent modifications
inhibit the ability of the antibiotic to bind the 16S rRNA and interfere with protein
synthesis (5). Over fifty enzymes have been identified which cause resistance to
aminoglycoside antibiotics (6). These enzymes include N-acetyltransferases, Ophosphotransferases, and O-nucleotidyltransferases. Each type of modifying enzyme
contains several members each of which is specific for modifying primarily at one
position on aminoglycoside molecules. Furthermore, each enzyme is capable of
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modifying several different aminoglycosides and each aminoglycoside antibiotic can be
modified by several different resistance enzymes.
One of the most important aminoglycoside modifying enzymes (AGMEs) is
aminoglycoside nucleotidyltransferase (2″) (ANT(2″)). This enzyme was first identified
in a clinical isolate of Klebsiella pneumoniae in 1971 (7). By 1985 ANT(2″) was the
most often detected aminoglycoside modifying enzyme in resistant clinical isolates in
North America and had been found in other continents in patients who had never traveled
outside their native country (8, 9). Despite the medical importance of this enzyme, very
little biochemical work has been done with this protein. This protein is difficult to isolate
in large quantities with a high level of purity (10, 11). Also this enzyme is relatively
unstable and has a low degree of solubility. ANT(2″) catalyzes the adenylation of
aminoglycosides which contain a hydroxyl group at the 2″ position (Figure 1). The
reaction is :

MgATP + Aminoglycoside

AMP-Aminoglycoside + MgPPi

Early work with ANT(2″) focused on correlation of in vitro substrate specificity
determined by kinetic assays with in vivo resistance determined by minimum inhibitory
concentration (MIC) testing. Data from these studies were often contradictory, probably
due to the use of different assays to monitor activity and the varying levels of purity of
enzyme preparations used in the in vitro studies (10-13). However one observation that
was consistent in these studies was substrate inhibition at increasing aminoglycoside
concentrations. Later, an extensive kinetic study quantified this substrate inhibition (14).
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Figure 1. The aminoglycosides used in this study are shown. The site of modification
(2″) and positions important in enzyme–substrate interactions (1,2′) are indicated on the
kanamycin A structure. In all the structures the deoxystreptamine ring (ring B) is in the
center with ring C which contains the double-prime (″) positions on the left and ring A
which contains the prime (′) positions on the right.
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This work also showed that the reaction followed an ordered Theorell-Chance
mechanism with the metal-nucleotide binding first, followed by the aminoglycoside
substrate (15). These studies were conducted with a mixture of two enzyme variants and
the amino acid sequence of the enzyme was not known. Even though the primary
sequence was not known, an analysis of the amino acid composition was reported (16).
The enzyme used by Gates and Northrop has a different composition than the one used in
the present study. However there is no evidence that the enzyme used in the present study
does not follow the mechanism originally proposed by Gates and Northrop.
We have cloned, overexpressed, and purified the aminoglycoside
nucleotidyltransferase(2")-Ia from Pseudomonas aeruginosa (17). The amino acid
sequence of ANT(2") does not show significant homology to any other aminoglycoside
nucleotidyltransferase (less than 5% identity and less than 15% similarity based on
BLAST searches and use of CLUSTALW to align the sequences (18, 19)). The acetyland phophotransferases are even less similar to ANT(2"). Thus the few wellcharacterized other AGMEs (3, 20) cannot be reliably used to predict characteristics of
this enzyme. Also this enzyme is one of only four of the over fifty known
aminoglycoside-modifying enzymes to modify primarily at positions on ring C of
aminoglycosides (Figure 1) (6). Most AGMEs modify positions on the A or B ring.
Because of the prevalence of this unique aminoglycoside-modifying enzyme, an
understanding of its interactions with substrates will be a useful tool in the fight against
drug-resistant bacteria. Here, we describe kinetic and thermodynamic properties of this
enzyme. A preliminary account of this work was presented earlier (21).
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Materials and Methods
Reagents. All materials were of the highest purity commercially available. All were
purchased from Sigma-Aldrich Co. (St. Louis, MO) except for inorganic
pyrophosphatase purchased from Roche Diagnostics Corp. (Indianapolis, IN),
dithiothreitol (DTT) purchased from Inalco Pharmaceuticals (Milano, Italy) and tris(2carboxyethyl)phosphine (TCEP) purchased from Fluka (Buchs, Switzerland). The
concentrations of adenosine 5′-triphosphate (ATP) and α,β-methyleneadenosine 5′triphosphate (AMPCPP) were determined by absorbance at 259 nm using an extinction
coefficient of 15,400 M-1 cm-1(22). The concentrations of kanamycin A and amikacin
were determined enzymatically using aminoglycoside phosphotransferase (3′)-IIIa
(APH(3′)) (23). The concentrations of the other aminoglycosides were determined by
one-dimensional NMR. The H1′ and H1″ proton peaks of tobramycin, kanamycin B,
sisomicin and isepamicin were integrated relative to the same proton peaks in the
kanamycin A and amikacin spectra. Glucose was used as an internal standard to ensure
uniform processing of spectra.
Protein preparation. ANT(2″) was prepared as described previously except that the
buffer was exchanged using a Sephadex G-25 column (30 cm x 1.0 cm) (17). For all
kinetic assays and circular dichroism experiments the final buffer is 50 mM TAPS1 pH
8.5, 50 mM KCl, 1 mM DTT and 0.1 mM EDTA. For all binding experiments
(Isothermal Titration Calorimetry (ITC), Electron Paramagnetic Resonance (EPR), and
fluorescence spectroscopy) the final buffer is 50 mM HEPES pH 7.5, 50 mM KCl and 1
mM TCEP.
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Kinetic assays. A discontinuous coupled enzyme assay based on the conversion of
one molecule of the reaction product inorganic pyrophosphate to two molecules of
inorganic phosphate was utilized to measure the steady-state rate of the reaction catalyzed
by ANT(2″) (17, 24). All reaction mixtures contained 50 mM TAPS pH 8.5, 2.0 units of
inorganic pyrophosphatase and a concentration of magnesium acetate to yield 5.0 mM
free magnesium at each concentration of ATP used in the assays. These concentrations
are based on the dissociation constant of MgATP calculated for the buffer used in the
assays (25). For the substrate specificity and temperature dependence assays the MgATP
concentration was 2.0 mM and each aminoglycoside concentration was varied from 10 to
500 µM. Each assay mixture contained 0.15–0.35 µM ANT(2″). The reaction was started
by the addition of aminoglycoside to the reaction mixture. Aliquots were removed at
various time points and added to 8% (w/v final) SDS in Acetic acid/Acetate buffer pH 4.0
to stop the reaction. The amount of inorganic phosphate was determined by previously
described methods (26, 27).
For the analysis of the substrate specificity and temperature dependence assays, the
data were fit to the following equation (28).

v=

VA
K m + A + A2 K i

(1)

where v is the measured rate from the kinetic assays, V is the maximal velocity, Km is the
substrate concentration that yields half-maximal velocity, Ki is the inhibition constant,
and A is the concentration of the varied substrate. The parameter kcat was calculated by
dividing the maximal velocity (V) by the enzyme concentration used in the assays. The
58

assay conditions for the comparison of magnesium and manganese as the divalent cation
were identical to the conditions for substrate specificity except for buffer and pH. The
magnesium vs. manganese assay mixture contained 50 mM HEPES pH 7.5 in place of 50
mM TAPS pH 8.5.
For temperature dependence assays the pH of each stock solution of buffer was
adjusted to 8.5 at the temperature of the assay. The reaction mixture except for enzyme
and aminoglycoside was incubated at the assay temperature for 10 min and the pH
confirmed prior to the start of each assay. For determination of the energy of activation
the data were plotted according to the equation:
ln k cat = −

Ea
+ ln A
RT

(2)

where kcat is the rate constant calculated using equation (1), R is the universal gas
constant (1.987 cal mol-1 K-1) and T is the temperature in degrees Kelvin. The activation
enthalpy, activation entropy, and Gibbs’ free energy of activation were determined
according to the equations:

ΔH ‡ = E a − RT

(3)

Ah
− 1)
k BT

(4)

ΔG ‡ = ΔH ‡ − TΔS ‡

(5)

ΔS ‡ = R(ln

where kB is the Boltzmann constant, h is Plank’s constant and A is the preexponential
factor determined using equation (2).
Circular Dichroism. Experiments were performed on an Aviv (Lakewood, NJ) model
202 spectrometer with a thermoelectric cell holder. A 2.0 mm path length cuvette
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containing 5.0 µM enzyme was used for each experiment. The sample chamber was
flushed extensively with nitrogen prior to data collection. The CD signal was monitored
at 222 nm as the temperature was increased in 3°C increments. A five minute
equilibration time was included at each temperature prior to data collection. The data in
figure 2 represent the average of three separate experiments. Data were collected in the
forward direction (increasing temperature) only. A reverse scan could not be performed
due to protein precipitation at higher temperatures.
Electron Paramagnetic Resonance. Continuous wave X-band (9.88 GHz) EPR spectra
of free Mn2+ were recorded using a Bruker (Billerica, MA) EMX spectrometer. All EPR
experiments were done at room temperature using a quartz capillary with a volume of
100 µL. Spectra were collected with 20 mW power, 100 kHz modulation frequency, 4.0
G modulation amplitude, 336 s sweep time and 4 scans. The spectra were baseline
corrected and integrated twice using the Win-EPR software from Bruker. A linear
relationship between the value for the second integral and the concentration of free
manganese was established over the entire range of manganese concentrations used in
these experiments. The dissociation constant for magnesium was determined by
competition with manganese as described previously using the equation (29):

K dMg =

[Mg 2+ ]1 2
[Mn 2+ ]
1+
K dMn

(6)

where [Mg2+]1/2 is the concentration of magnesium required to displace half of the bound
manganese.
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Figure 2. The temperature dependence of the reaction catalyzed by ANT(2″) is shown in
the top panel. The assays were performed at pH 8.5 and contained 2.0 mM MgATP. The
free magnesium concentration was 5 mM and the tobramycin concentration was varied
from 10 to 500 µM. The kcat values were calculated using equation 1. The lower panel
shows the molar ellipticity as a function of temperature as determined by circular
dichroism.
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Isothermal titration calorimetry. ITC experiments were performed at 20°C using a
VP_ITC microcalorimeter from Microcal, Inc. (Northampton, MA). Ligand solutions
were prepared using the mobile phase from the Sephadex G-25 column used for desalting
the enzyme. Both enzyme and ligand solutions were degassed under vacuum for 10 min
at 15°C. Titrations consisted of 29 injections of 10 µL and were separated by 240 s. Cell
stirring speed was 300 rpm. Each titration contained 5–10 µM enzyme in the sample cell.
For binary enzyme:tobramycin2 and quaternary enzyme–MgAMPCPP:tobramycin
complexes, the tobramycin concentration was 60–120 µM in the injection syringe. For
the quaternary titrations the sample and ligand solutions each contained 2.0 mM MgCl2
and 0.8 mM AMPCPP. For the enzyme:MgATP titrations with excess free magnesium,
the enzyme and ligand solutions each contained 5.5–6.0 mM MgCl2. The ligand solution
contained 0.4–0.8 mM ATP. For the enzyme:MgATP titrations with minimal free
magnesium, no magnesium was present in the enzyme solution. The ligand solution
contained 0.45 mM MgCl2 and 0.65 mM MgATP. The standard errors represent the
deviation including curve fitting errors of the three titrations. Two titrations using
AMPCPP instead of ATP in the enzyme:metal–nucleotide titrations were done to ensure
MgAMPCPP binding was similar to MgATP binding to enzyme. Titrations of ATP into
the enzyme solution in the absence of Mg2+ were performed by using 2–10 mM ATP in
the syringe.
All data were fit to the single-site binding model of Origin 5.0 (Microcal, Inc) to
determine the binding constant (Ka), enthalpy of binding (ΔH) and stoichiometry (30).
The free energy (ΔG) and entropy (ΔS) changes associated with binding were determined
using the equations:
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ΔG = −RT ln K a

(7)

ΔG = ΔH − TΔS

(8)

Fluorescence Spectroscopy. Fluorescence quenching experiments using ATP and
MgATP were performed on a Perkin-Elmer (Boston, MA) model LS-5B
spectrofluorimeter. For each titration 2–5 µL aliquots from a concentrated stock solution
of ATP or MgATP was added to 2.0 mL of 1.0 µM ANT(2″) at room temperature. The
excitation wavelength was 295 nm and the fluorescence emission at 340 nm was
measured. Fluorescence intensities were corrected for dilution, scattering and the inner
filter effect. The data were fit to the following equation:

ΔFmax
× 100 ) × [S ]
F0
ΔF
(
× 100 ) =
K d + [S ]
F0
(

(9)

where (ΔF/F0 x 100) is the percent change in fluorescence resulting from the addition of
substrate at a concentration [S].

Results
Substrate specificity of ANT(2″). Although several studies of the substrate profile of
ANT(2″) have been undertaken, many used only partially purified enzyme (10). Some
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used enzyme assays which were linear only at very low substrate concentrations and
required distant extrapolation to estimate kinetic values (13). In the most comprehensive
study of the kinetics of aminoglycoside nucleotidyltransferase (2″) to date, two
electrophoretic variants of ANT(2″) were used in the assays (15). It is not known whether
the two species were due to two different start sites, a covalent modification of one of the
species or some other reason (16). In the present study the nature of the ANT(2″) utilized
is well-defined. The amino acid sequence is known from DNA sequencing. We used the
226 amino acid version of the enzyme, which has been shown to have higher specific
activity than ANT(2″) translated from other start sites (17).
Of the aminoglycoside substrates used in this study, tobramycin and kanamycin B had
the highest kcat/Km values (Table 1). The fact that these two substrates had similar kinetic
properties is not surprising since these molecules differ only at the 3′ position (Figure 1).
Kanamycin A, however, differs from kanamycin B only at the 2′ position, yet the Km for
kanamycin A is two-fold greater than that observed for kanamycin B. These data
illustrate the importance of the 2′ position in aminoglycoside binding to enzyme. Also,
amikacin and isepamicin had approximately two orders of magnitude lower kcat/Km when
compared to kanamycin B and tobramycin, which may explain why ANT(2″) does not
confer resistance to these antibiotics.
Similar to observations made with some of the other AGMEs, substrate inhibition is
observed with ANT(2″). The inhibition constant, Ki, shows similar substrate dependence
to that observed with Km values even though these two parameters, Ki and Km, reflect
interactions with different forms of the enzyme. The Ki of kanamycin A is over four-fold
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Table 1: Kinetic parameters of selected aminoglycoside substrates of ANT(2″)
Substrate
kcat (s-1)
Km (µM)
kcat/Km (M-1 s-1)
Ki (µM)
4
Tobramycin
2.01 ± 0.14
22.1 ± 3.2
9.10 × 10
74 ± 8.1
Kanamycin B
1.77 ± 0.10
20.1 ± 3.4
8.81 × 104
81 ± 14
4
Sisomicin
3.12 ± 0.27
52.6 ± 5.8
5.93 × 10
226 ± 36
Kanamycin A
1.96 ± 0.19
49.9 ± 6.3
3.93 × 104
443 ± 81
3
ndb
Amikacin
0.17 ± 0.03
84.1 ± 9.2
2.02 × 10
Isepamicin
0.19 ± 0.04
163.6 ± 44
1.16 × 103
ndb
a
Data represent average of three separate determinations.
b
Substrate inhibition not detected at substrate concentrations up to
0.5 mM.
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higher than kanamycin B. The difference in Ki values between kanamycin A and
kanamycin B also confirms the importance of the substituent at the 2′ position in
aminoglycoside–enzyme interactions (Figure 1). Tobramycin, which has an amino group
at the 2′ position, also follows the same pattern and has a Ki value very similar to
kanamycin B. Ki values for amikacin and isepamicin could not be determined because no
inhibition was observed even at high concentrations (0.5 mM) of substrates. This is
consistent with high Km values observed for these two aminoglycosides.
The substrate with the highest maximal rate per unit enzyme (kcat) is sisomicin. This
aminoglycoside contains an unsaturation at position 4′ rather than a hydroxyl. Otherwise
the A and B rings are identical to tobramycin (Figure 1). The kcat values for tobramycin,
kanamycin A and kanamycin B were very similar. Both amikacin and isepamicin are very
poor substrates for ANT(2″) showing that the alkyl group attached to the 1-NH2 position
of the deoxystreptamine ring in these two aminoglycosides interferes with binding and
activity.
Temperature Dependence of Catalysis by ANT(2″). The temperature dependence of
the rate of the reaction catalyzed by ANT(2″) was determined using tobramycin as the
aminoglycoside substrate. The rate increased steadily between temperatures 15°C and
30°C, reached a plateau around 32°C, and started to decline steeply above 35°C (Figure
2). The optimum temperature for activity of ANT(2″) is 30-32°C. This optimum is
unusual since this enzyme is present in resistant bacteria within the human body. From
the circular dichroism data, shown in Figure 2, it is clear that the enzyme begins to lose
secondary structure above 32°C. This could be because the buffer used in these assays
does not adequately mimic conditions inside the cell. The buffer system was chosen
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because it resulted in the highest enzymatic activity. Increasing salt concentration had no
effect on temperature dependence. Only the use of at least 5% glycerol or ethylene glycol
increased the temperature optimum to 37-40°C (data not shown).
Data obtained from the temperature dependence of activity measurements were used
to construct an Arrhenius plot, which yielded a straight line for temperatures between
15°C and 30°C (Figure 3). An activation energy of 19.2 kcal/mol was determined from
the Arrhenius plot of the data. The activation enthalpy (ΔH‡) is 18.6 kcal/mol, the
activation entropy (ΔS‡) is 3.9 cal/mol K and the Gibbs’ free energy of activation (ΔG‡)
is 17.4 kcal/mol at 25°C. These results show that the reaction barrier is primarily
enthalpic for the reaction catalyzed by ANT(2″).
Manganese alters substrate specificity. Although magnesium is the preferred divalent
cation required for ANT(2″) activity, a paramagnetic metal was needed to study metal
binding to ANT(2″) by EPR. Therefore the effect of Mn2+ on the catalytic activity of the
enzyme was studied. Interestingly, the effect of the substitution of MnATP for MgATP
was dependent on the aminoglycoside substrate (Figure 4). Catalytic activity of the
enzyme was only 7–12% of what was observed with MgATP when tobramycin,
kanamycin B, or sisomicin were used as the aminoglycoside substrate with MnATP. In
contrast to this, the activity of enzyme was greater than 70% with MnATP as compared
to the activity observed with MgATP when kanamycin A was used as substrate (Figure 4,
A and B). All four aminoglycosides tested showed a similar decrease in Km resulting in
the kcat/Km profile seen in panel D of Figure 4. Thus, it appears that kanamycin A is a
poorer substrate than tobramycin, kanamycin B or sisomicin when MgATP is the metal–
nucleotide substrate but becomes a better substrate than the other aminoglycosides when
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Figure 3. An Arrhenius plot constructed from the data for temperatures 15 to 30°C in
figure 2 is shown. The slope of the linear fit of the data was used to calculate the
activation energy.
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Figure 4. The substitution of manganese for magnesium as the required divalent cation
alters the substrate specificity of ANT(2″). Panels A and C show the kinetic data for
magnesium as the required metal. Panels B and D show the kinetic data for manganese as
the required metal. The assays were performed at pH 7.5. Each assay mixture contained
2.0 mM metal–nucleotide and 5.0 mM free divalent cation. The aminoglycoside
concentration was varied from 10 to 500 µM and the data fit to equation 1.
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MnATP is the metal-nucleotide substrate. This phenomenon of altered substrate
specificity in the presence of manganese versus magnesium has been observed previously
in enzymes such as HIV-1 integrase and RNA dependent RNA polymerase (31, 32). For
ANT(2″) the reason for this phenomenon is not apparent. It could be due to the metal–
nucleotide complex or the free divalent cation that binds to the enzyme (see next section).
In either case, one difference between kanamycin A and the three of the other
aminoglycosides studied with manganese is that kanamycin A is the only aminoglycoside
with a hydroxyl substituent at the 2′ position while tobramycin, kanamycin B and
sisomicin have an amine at that position.
Metal-binding to ANT(2″). The use of EPR as a tool to determine metal-protein
binding affinities is well-established (33). The binding of manganese to enzyme broadens
the EPR signal to undetectable levels. Thus, the decrease in signal can be quantified to
determine the amount of free and bound Mn2+ in solutions containing enzyme and Mn2+.
Solutions with ANT(2″) and buffer alone containing matched concentrations of Mn2+
were used to determine free and bound Mn2+ by EPR. Several different ratios of
manganese to enzyme were utilized. Results are shown in Figure 5 in the form of a
Scatchard plot. As shown in Figure 5, Mn2+ binds to 0.94 ± 0.09 sites on this enzyme
with a dissociation constant of 23 ± 3 µM. Addition of Mg2+ to a solution containing
enzyme–Mn2+ complex displaced the enzyme-bound Mn2+ and a complete displacement
of Mn2+ occurred at higher concentration of Mg2+. A dissociation constant of 111 ± 24
μM was then determined for the enzyme–Mg2+ complex by the titration of enzyme–Mn2+
complex with Mg2+ (Figure 5, lower panel). Although magnesium and manganese are
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Figure 5. Scatchard analysis shows that one manganese ion binds to the enzyme with a
dissociation constant of 23 ± 3 µM (top panel). The displacement of manganese by
magnesium in solutions containing 20 µM ( ) and 50 µM ( ) manganese(II) and 15 μM
enzyme. This data is used to determine the binding affinity of magnesium(II) to enzyme.
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both divalent cations of similar size, manganese binds to the enzyme four to five times
tighter than magnesium. The tighter binding by manganese to enzyme has been observed
in several other proteins including glutamine synthetase and T7 RNA polymerase (34,
35).
When Mn2+ binding experiments were performed in the presence of ATP the
stoichiometry of bound manganese(II) to the enzyme was increased to 1.8 ± 0.3 (Figure
6). This result suggests that one manganese ion is capable of binding to the enzyme
independent of the nucleotide and one binds as MnATP. In these titrations, a further
decrease of the free manganese signal was observed after the addition of Mn2+ sufficient
to completely saturate the ATP. This decrease shows that a divalent cation other than the
one present in the metal–nucleotide complex binds to enzyme. Additional EPR
experiments confirmed that manganese binds ATP with a one-to-one stoichiometry with
a dissociation constant of 8 ± 3 µM. This is similar to values found earlier for the
dissociation constant of MnATP (36). Scatchard analysis could not distinguish between
the two binding events because the dissociation constants for the two binding events are
similar to each other (8 µM vs. 23 µM). Kinetic data also support these observations; the
amount of magnesium required for optimal activity is much greater than the amount
required to saturate ATP (10). The requirement of two metals for activity is not unusual
in ATP-utilizing enzymes. The presence of two metal ions in the active site is observed in
the aminoglycoside-modifying enzyme APH(3′) (37). Also, several other nucleotidyltransferring enzymes such as DNA and RNA polymerases require two metals for activity
(38-41). On the other hand, only one metal per monomeric unit is observed in the crystal
structure of the other clinically relevant nucleotidyltransferase, aminoglycoside
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Figure 6. ATP changes the the stoichiometry from 0.94 ± 0.09 to 1.8 ± 0.3 divalent
cations per molecule of enzyme. The linear curve fit for binding in the absence of
nucleotide (from Figure 6, top) without data points is shown for comparative purposes.
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nucleotidyltransferase(4′,4″) (42). Thus, in the absence of structural data, the existence of
an additional metal binding site away from the active site, though less likely, can not be
excluded.
Thermodynamic properties of enzyme–substrate complexes. The binding of substrates
to ANT(2″) was studied by ITC. Titrations of MgATP to the enzyme were performed
under two different sets of conditions: in the presence and absence of excess Mg2+. These
conditions were selected on the basis of the change in stoichiometry of Mn2+ binding to
the enzyme in the presence of ATP (Figures 5 and 6). In the presence of 5 mM free
magnesium, the dissociation constant for the enzyme:MgATP was 12 μM (Figure 7). In
the absence of excess Mg2+, the affinity of MgATP to the enzyme decreased slightly,
indicating that the second metal ion does not play a significant role in metal–nucleotide
binding to enzyme (Table 2). In both cases the stoichiometry of binding was 1:1
MgATP:ANT(2″) and enthalpic and entropic contributions to binding were favorable.
Interestingly, titration of enzyme with ATP in the absence of any metal ions did not show
an observable heat change signal. The possible explanations are that free ATP binds very
weakly or not at all to this enzyme or coincidentally no net heat change is observable at
this temperature. Fluorescence experiments were performed to differentiate between
these two possibilities. ANT(2″) has eight tryptophan residues. The change in tryptophan
fluorescence as a result of adding ATP or MgATP to solutions containing the enzyme
showed that ATP binds much weaker than MgATP (Figure 8). The dissociation constant
of enzyme:ATP complex, determined by fluorescence spectroscopy, was 530 µM. In
titrations containing Mg2+, the enzyme solution contained matching concentration (5
mM) of free Mg2+ to the free Mg2+ in MgATP solution. Thus, the change in fluorescence
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Figure 7. The binding isotherm from the titration of MgATP to enzyme in the presence
of excess magnesium is shown. Reproducible results were obtained with only 5-10 µM
enzyme in the sample cell to obtain thermodynamic parameters for this interaction.
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Table 2: Thermodynamic parameters of aminoglycoside and metal-nucleotide binding to
ANT(2″) determined by ITC
KD
ΔH
TΔS
ΔG
(µM)
(kcal/mol)
(kcal/mol K)
(kcal/mol)
E MgAMPCPP : Tob
0.21 ± 0.09
-12.6 ± 0.3
-3.6
-9.0
E : Tob
0.64 ± 0.17
-18.2 ± 0.4
-10.0
-8.2
a
12.1 ± 3.6
-2.4 ± 1.2
4.5
-6.9
E : MgATP
E : MgATPb
18.4 ± 5.0
-3.8 ± 1.7
2.8
-6.6
c
E : ATP
nd
nd
nd
nd
a
Contained 5 mM excess Mg2+
b
Contained minimal free Mg2+ (less than 25 µM)
c
No heat change was observed using 2–10 mM ATP titrated into 10 µM enzyme in the
absence of Mg2+ at 20°C.
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Figure 8. The change in intrinsic tryptophan fluorescence of ANT(2″) as a result of
nucleotide binding shows that MgATP (top) has a much higher affinity for enzyme than
free ATP (bottom).
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could be attributed to the metal–nucleotide binding and not binding of free magnesium to
the enzyme. A dissociation constant of 15 ± 3 µM was determined for MgATP which
agrees well with the dissociation constant determined by ITC for the same complex.
Binding of the aminoglycoside substrate to the enzyme was investigated using
tobramycin as the substrate. Tobramycin was chosen for these studies since it had the
lowest Km and Ki values of the aminoglycoside substrates tested kinetically (Table 1). As
shown in Figure 9, binding of tobramycin to ANT(2″) is an exothermic reaction.
However, unlike metal–ATP binding, the binding of tobramycin to the enzyme is
entropically disfavored, which was compensated for by a large enthalpic contribution
yielding a favorable ΔG for the complex formation. Stoichiometry of the binding was 1:1
tobramycin:enzyme and a dissociation constant of 0.64 μM was determined for the
enzyme:tobramycin complex. This value is two orders of magnitude lower than the
kinetically determined Ki value. The dissociation constant was reduced three-fold in the
presence of saturating metal–nucleotide in the form of the non-hydrolyzable ATP analog,
AMPCPP and excess magnesium. Although the enthalpy was less negative in the
quaternary complex, the entropic penalty (TΔS) was much lower compared to the binary
enzyme–tobramycin complex (Table 2).

Discussion
This study reports the first kinetic comparison of aminoglycoside substrates that uses
a single isoform of the enzyme with a known amino acid sequence. This work confirms
the importance of the substituent at the 2′ position in aminoglycoside binding to a 2″nucleotidyltransferase which was first described by Gates and Northrop (14). The
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Figure 9. The binding of the tobramycin to ANT(2″) in the absence(left) and presence
(right) of MgAMPCPP. The presence of metal–nucleotide increases the affinity of
aminoglycoside to enzyme.
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importance of this position has also been reported for other aminoglycoside-modifying
enzymes (23, 43, 44). However in these enzymes the Km and kcat are both decreased for
aminoglycosides containing a hydroxyl rather than an amine at the 2′ position with little
effect on kcat/Km. For ANT(2″) Km is increased while kcat is unaffected by the replacement
of a hydroxyl with an amine at this position which results in a much lower kcat/Km for
aminoglycosides like kanamycin A (2′ -OH) compared to tobramycin or kanamycin B (2′
-NH2). The importance of position one of the deoxystreptamine ring in aminoglycoside
binding to ANT(2″) is also apparent from these results since isepamicin and amikacin are
very poor substrates for this enzyme. These data illustrate why ANT(2″) does not confer
resistance against these two aminoglycosides even though they each contain a hydroxyl at
the 2″ position. These semisynthetic aminoglycosides are also poor substrates for other
aminoglycoside-modifying enzymes (6, 45). Even though ANT(2″) is unusual in that it
does not share a significant degree of homology with other aminoglycoside-modifying
enzymes and modifies on the double-prime ring, it is not surprising that the same groups
are important for aminoglycoside binding to the enzyme. The A and B rings of
aminoglycoside antibiotics adopt similar conformations when bound to aminoglycosidemodifying enzymes (46-48). This similarity occurs not only within all three classes of
aminoglycoside-modifying enzymes but also in enzymes that modify on each of the three
different rings (49). These similarities prompted the hypothesis that these two rings form
the basic structural unit recognized by many AGMEs (46). Although these similarities
may seem to provide a rationale for the design of aminoglycoside antibiotics less
susceptible to resistance enzymes, these two positions are also important for
aminoglycoside binding to RNA (50). Therefore altering these positions on the drug will
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likely reduce its potency which has been observed with deaminated analogs of kanamycin
A and neamine (51). Also the increased usage of amikacin has led to the emergence of
resistance enzymes which efficiently modify this aminoglycoside (52, 53).
This study also measured the binding of substrates and cofactors to ANT(2″). The
binding events associated with the formation of the catalytically competent complex are
summarized in Scheme 1 and Table 3. Both fluorescence and ITC experiments show that
metal–nucleotide binds much tighter than free nucleotide. This result supports kinetic
data which predicted MgATP and not free ATP as the true substrate. The presence of
magnesium or manganese is required for ATP to bind to the enzyme with high affinity.
Binding studies performed by EPR reveal a separate divalent cation binding site on the
enzyme in addition to the metal–ATP binding site. The affinity for the second metal
binding is increased by the presence of metal–ATP. This second binding site is likely to
be near the catalytic site because kinetic studies indicated that the full activity of the
enzyme requires the presence of additional free divalent cation in addition to metal–ATP.
It is possible that the two divalent cations share aspartate ligands on the protein. This
feature has been observed in several members of the nucleotidyltransferase superfamily
(38-41, 54, 55). Both divalent cations are thought to stabilize the transition state in this
mechanism. One metal facilitates the nucleophilic attack while the other helps the exit of
the pyrophosphate (40, 56). A model for the role of the two metals for ANT(2″) is
presented in figure 10.
The binding of metal-nucleotide also makes the binding of aminoglycoside more
favorable. The presence of MgAMPCPP reduces the enthalpic contribution, however, the
entropic contribution becomes more favorable and yields a slightly more favorable ΔG
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Scheme I.

82

Table 3: Dissociation constants of complexes shown in Scheme 1
Parameter
Definition
Kd
(E)(Mg2+) ⁄ (EMg)
Kd′
(EMgATP)(Mg2+) ⁄ (EMgMgATP)
K2
(E)(MgATP) ⁄ (EMgATP)
K2′
(EMg)(MgATP) ⁄ (EMgMgATP)
K3
(EMgMgAMPCPP)(Tob) ⁄ (EMgMgAMPCPPTob)a
KS
(E)(Tob) ⁄ (ETob)
K1
(E)(ATP) ⁄ (EATP)
a
The ATP analog AMPCPP was used to estimate K3
The dissociation constants were determined by bEPR, dITC, and
e
fluorescence.
c
Calculated from the relation K2Kd′ = K4Kd

KD (µM)
111 ± 24b
38 ± 9c
18.4 ± 5.0d
12.6 ± 3.6d
0.21 ± 0.08d
0.64 ± 0.17d
530 ± 40e
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Figure 10. A model for the role of the two metals in the nucleotidyl transfer catalyzed by
ANT(2″). Metal A facilitates the nucleophilic attack on the α-phosphate of ATP and
metal B aids the pyrophosphate leaving group. Both metals stabilize the transition state.
This figure is adapted from references 39 and 56.
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for the enzyme–MgAMPCPP:tobramycin complex compared to the binary
enzyme:tobramycin complex. The binding of tobramycin to ANT(2") in the absence of
metal–nucleotide is driven by favorable enthalpic contribution which compensates the
large entropic penalty and yields a favorable ΔG for the complex formation. This is
similar to what is observed with tobramycin binding to the aminoglycoside
phosphotransferase (3')-IIIa (57). The largely exothermic nature of the interaction of
aminoglycoside with ANT(2″) explains the large activation enthalpy associated with this
reaction since the release of adenylated aminoglycoside is thought to be the rate
determining step of this reaction (58). Finally, the tight binding of tobramycin to enzyme
in the absence of metal–nucleotide may appear to contradict earlier work in which the
origin of substrate inhibition was determined to arise from aminoglycoside binding to
enzyme complexed with adenylated aminoglycoside and inhibiting product release (15).
The results of the two studies cannot be directly compared because the earlier kinetic
assays were done at pH 9.1 while the binding experiments in the present work were done
at pH 7.5.
Even though the aminoglycoside binding is much tighter than MgATP binding, the
ordered sequential mechanism is still efficient at modifying aminoglycosides and
providing resistance to the bacteria. In the cell the concentration of MgATP and Mg2+ is
much higher than aminoglycoside concentration. Initially aminoglycoside concentration
within the cell is very low. Only after the initial effects on protein translation lead to an
increase in permeability of the membrane do large amounts of aminoglycoside enter the
cell (59, 60). Therefore, in the presence of modifying-enzymes the amount of
aminoglycoside remains low. These properties also explain why resistance in vivo for
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ANT(2″) as well as other aminoglycoside-modifying enzymes correlates better with
kcat/Km rather than kcat (61, 62).
Detailed structural information from X-ray crystallography or NMR will be difficult to
obtain due to the instability of this enzyme and its tendency to form oligomers at
concentrations above 40 µM concentration. Also, structural predictions based on amino
acid sequence homology are not possible with this enzyme. Therefore the use of
biophysical techniques to study ANT(2″) is currently the best strategy to gain insight into
this important antibiotic resistance conferring enzyme. Also, comparison of the attributes
of this enzyme with the better characterized aminoglycoside-modifying enzymes can
provide strategies to design inhibitors of aminoglycoside-modifying enzymes and
possibly antibiotics which are not susceptible to resistance enzymes.
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Abstract
One of the most commonly occurring aminoglycoside resistance enzymes is
aminoglycoside 2″-O-nucleotidyltransferase, ANT(2″). In the present study molecular
determinants of affinity and specificity for aminoglycoside binding to this enzyme are
investigated using isothermal titration calorimetry (ITC). Binding of aminoglycosides is
enthalpically driven accompanied by negative entropy changes. The presence of metal–
nucleotide increases the affinity for all but one of the aminoglycosides studied, but has no
effect on specificity. The substituents at positions 1, 2′, and 6′ are important determinants
of substrate specificity. An amino group at these positions leads to greater affinity. No
correlation is observed between the change in affinity and enthalpy. At the 2′ position
greater affinity results from a more negative enthalpy for an aminoglycoside containing
an amino rather than a hydroxyl at that position. At the 6′ position the greater affinity for
an aminoglycoside containing an amino substituent results from a less disfavorable
entropic contribution. The thermodynamic basis for the change in affinity at position 1
could not be determined because of the weak binding of one of the aminoglycoside
substrates, amikacin. The importance of these three positions on rings A and B of may
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also provide the rationale for the ability of ANT(2″) to confer resistance against
kanamycins but not neomycins.

Introduction
The increasing incidence of bacteria resistant to treatment with antibiotics is a major
concern for the medical community. One class of antibiotics particularly susceptible to
resistance are the aminoglycoside antibiotics. This group of antibiotics is important
because they are often used to treat hospital-acquired infections caused by Gram-negative
bacteria. Resistance to aminoglycosides may be caused by a number of mechanisms
including altered target RNA, decreased membrane permeability or drug efflux pumps (1,
2). The most prevalent cause of resistance, however, is covalent modification of
aminoglycosides by aminoglycoside-modifying enzymes (AGMEs) (3). Three classes of
AGMEs exist. These include N-acetyltransferases which catalyze the acetyl-CoAdependent acetylation of an amino group on an aminoglycoside, O-phosphotransferases
which catalyze the ATP-dependent phosphorylation of an aminoglycoside and Onucleotidyltransferases which catalyze the ATP-dependent adenylylation of an
aminoglycoside. Each type of AGME has several members regiospecific primarily for
one position on aminoglycoside compounds. Most of these enzymes are capable of
modifying several different aminoglycosides. Also, since several different enzymes exist
which can modify at different positions, each aminoglycoside is capable of being
modified by several different enzymes (4).
One of the most prevalent of these enzymes is aminoglycoside
nucleotidyltransferase(2″)-Ia (ANT(2″)). ANT(2″) catalyzes the direct nucleophilic attack
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on the α-phosphate of ATP producing AMP–Aminoglycoside.(5) This enzyme provides
resistance against tobramycin, kanamycin, gentamicin and other aminoglycoside
antibiotics. ANT(2″) is one of the most frequently occurring AGMEs. This enzyme has
been detected in a large percentage of resistant Gram-negative bacteria in North America
as well as the other inhabited continents (6, 7).
Most clinically useful aminoglycoside antibiotics consist of a central 2deoxystreptamine ring with amino sugars attached by glycosidic bonds at either positions
4 and 6 (4,6-disubstituted) or positions 4 and 5 (4,6-disubstituted). ANT(2″) is unusual in
that it is one of only two clinically relevant AGMEs that modify predominantly on ring
C of 4,6-disubstituted 2-deoxysreptamines (Figure 1). The other enzyme which modifies
primarily on this ring is aminoglycoside phosphotransferase (2″) (APH(2″)). This AGME
is usually found as part of the bifunctional enzyme AAC(6′)-APH(2″). This enzyme is
different than ANT(2″), however in that it can also modify 4,5-disubstituted 2deoxystreptamines. APH(2″) is capable of phosphorylating 4,5-disubstituted
aminoglycosides (8). ANT(2″) is only capable of modifying 4,6-disubstituted
aminoglycosides.
Previous studies determining the substrate specificity of ANT(2″) have used kinetic
studies to compare the aminoglycoside substrates (9-12). In this work we use isothermal
titration calorimetry (ITC) to directly measure the binding affinity of various
aminoglycosides for ANT(2″). Thermodynamic parameters for the binding of different
aminoglycosides are also determined. ITC has been used previously to characterize
aminoglycoside binding to the aminoglycoside acetyltransferase AAC(6′)-Iy (13) and the
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Figure 1: Structures of the aminoglycoside antibiotics used in this study. The positions
on the A ring are designated as the prime (′) positions and the positions on the C ring are
designated the double prime (″) positions.
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aminoglycoside phosphotransferase APH(3′)-IIIa.(14) Thermodynamic parameters for
MgATP and tobramycin binding have been reported recently for ANT(2″) (15).

Materials and Methods
Reagents. All materials were of the highest purity commercially available. All were
purchased from Sigma-Aldrich Co. (St. Louis, MO) except for tris(2carboxyethyl)phosphine (TCEP) purchased from Fluka (Buchs, Switzerland).
Protein preparation and kinetic assays. ANT(2″)-Ia was prepared as described
previously (16). Immediately prior to use in ITC experiments, the protein was desalted
using a Sephadex G-25 column. Kinetic assays of the enzyme were also performed as
described previously (15). All assays were done at pH 7.5. All assay mixtures contained
10 mM MgCl2 and 1.0 mM ATP. The concentration of tobramycin was varied from 10 to
500 µM. The concentrations of inhibitor were 0, 0.375, 0.75 and 1.5 mM. Kinetic data
were fit to equation (1) to determine the kinetic parameters and type of inhibition. Data
were fit to equation (2) to determine the inhibition constants for neomycin B and
paromomycin:
v=

VA
K m + A + A 2 K i , sub

K m,app = K m (1 + [ I ] K i ,comp )

(1)

(2)

where v is the measured rate of the reaction, V is the maximal velocity, A is the
concentration of tobramycin, Km is the substrate concentration that yields half-maximal
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velocity and Ki,sub is the inhibition constant for substrate inhibition. Km,app is the apparent
Km in the presence of competitive inhibitor and Ki,comp is the inhibition constant for the
competitive inhibitor. The competitive inhibition constants determined at each
concentration of inhibitor were averaged to obtain the values and standard errors for the
inhibition by neomycin B and paromomycin I described in the results and discussion
section.
Isothermal titration calorimetry. ITC experiments were performed at 20°C using a VPITC microcalorimeter from Microcal, Inc. (Northampton, MA). Ligand solutions were
prepared using the mobile phase from the Sephadex G-25 column used for desalting the
enzyme. The final buffer for ITC experiments was 50 mM HEPES or PIPES pH 7.5, 50
mM KCl and 2 mM TCEP. Both enzyme and ligand solutions were degassed under
vacuum for 10 min at 15°C. Titrations consisted of 29 injections of 10 µL and were
separated by 240 s. Cell stirring speed was 300 rpm. Each titration contained 5–20 µM
enzyme in the sample cell. For binary enzyme–aminoglycoside and quaternary enzyme
MgAMPCPP–aminoglycoside complexes, the aminoglycoside concentration was 60–150
µM in the injection syringe. For the quaternary titrations the sample and ligand solutions
each contained 5.0 mM MgCl2 and 0.8 mM AMP-CPP. The standard errors represent the
deviation including curve fitting errors of the three titrations. The c values (c = KaMt,
where Mt is the concentration of macromolecule binding sites) (17) for all experiments
except the amikacin titrations were in the range 5–20. This range is ideal for accurately
determining binding constants by ITC. For titrations using amikacin the c values ranged
from 0.2-0.5.
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All data were fit to the single-site binding model of Origin 5.0 (Microcal, Inc) to
determine the binding constant (Ka), enthalpy of binding (ΔH) and stoichiometry (n) (17).
The free energy (ΔG) and entropy (ΔS) changes associated with binding were determined
using the equations:

ΔG = − RT ln K a

(3)

ΔG = ΔH − TΔS

(4)

Determination of the intrinsic enthalpy of binding was determined by the simultaneous
solutions of the equations:

ΔH obs1 = ΔH int + ΔH ion1Δn

(5a)

ΔH obs 2 = ΔH int + ΔH ion 2 Δn

(5b)

where the subscripts 1 and 2 refer to different buffers, ΔHobs is the observed enthalpy
change upon binding, ΔHion is the heat of ionization of the buffer and Δn is the net uptake
of protons by the buffer upon complex formation. The heat of ionization for HEPES is
+4.87 kcal/mol and for PIPES is +2.67 kcal/mol (18).
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Results and Discussion

Thermodynamics of aminoglycoside binding. The binding interactions between
ANT(2″) and seven different aminoglycoside antibiotics were studied by ITC. Titrations
of the aminoglycosides to enzyme alone (binary complex) were performed. Also,
titrations of aminoglycosides to enzyme saturated with MgAMPCPP, an MgATP analog,
were performed. All titrations were performed in two different buffers to determine the
intrinsic enthalpy of binding (ΔHint). The observed enthalpy change (ΔHobs) in an ITC
experiment reflects contributions from both the intrinsic enthalpy of the reaction and the
change in enthalpy due to release or uptake of protons by the buffer (19, 20).
The results are presented in tables 1 and 2. For one of the aminoglycosides studied,
amikacin, the affinity was too low to obtain accurate values for ΔH and TΔS. All binding
interactions were characterized by favorable enthalpy (−ΔH) and unfavorable entropy
(−TΔS). The binding was tighter in the presence of MgAMPCPP for all aminoglycosides
studied with the exception of sisomicin. In the case of sisomicin the dissociation constant
is similar in the presence and absence of metal-nucleotide. For sisomicin, a member of
the gentamicin family of 4,6-disubstituted aminoglycosides, a slightly more negative
enthalpy and slightly more negative entropy in the presence of MgAMPCPP results in a
similar free energy of binding. For the members of the kanamycin family of 4,6disubstituted aminoglycosides, kanamycin A, kanamycin B and tobramycin, the presence
of MgAMPCPP resulted in a two to threefold decrease in the dissociation constant. For
all three of these substrates a less favorable (less negative) enthalpy of binding was
overcome by a decrease in the unfavorable entropic contribution resulting in overall
greater affinity when ANT(2″) is saturated with metal-nucleotide. For the 4,5104

Table 1: Thermodynamic parameters for aminoglycoside binding to ANT(2″) (binary
complex) at pH 7.5a
KD
ΔHobsb
ΔHint
-TΔS
ΔG
Buffer
(µM)
(kcal/mol) (kcal/mol) (kcal/mol) (kcal/mol)
kanamycin A
HEPES
2.6
-15.6
8.1
-7.5
-22.4
PIPES
3.0
-18.7
11.3
-7.4
kanamycin B
HEPES
0.44
-21.4
10.3
-8.5
-27.8
PIPES
0.62
-24.3
13.9
-8.3
tobramycin
HEPES
0.64
-18.2
10.0
-8.2
-26.6
PIPES
0.83
-22.0
13.9
-8.1
sisomicin
HEPES
1.7
-14.3
6.6
-7.7
-21.2
PIPES
1.2
-17.4
9.5
-7.9
paromomycin I HEPES
11.5
-16.3
9.7
-6.6
-19.2
PIPES
7.3
-17.6
10.7
-6.9
neomycin B
HEPES
0.53
-14.3
5.9
-8.4
-18.3
PIPES
0.59
-16.4
8.1
-8.3
amikacin
HEPES
~60
NDc
ND
ND
-5.7
a
Determined at 293 K. Error values: KD, 4-13%, ΔH, 1-5%. The stoichiometry of
complex formation was 1.0 ± 0.2 for all titrations.
b
Intrinsic enthalpy change determined using equations 5a and 5b.
c
ND, not determined.
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Table 2: Thermodynamic parameters for aminoglycoside binding to ANT(2″) in the
presence of MgAMPCPP and excess Mg2+ (Quaternary complex) at pH 7.5a
KD
ΔHobsb
ΔHint
-TΔS
ΔG
Buffer
(µM)
(kcal/mol) (kcal/mol) (kcal/mol) (kcal/mol)
kanamycin A
HEPES
1.1
-14.1
6.1
-8.0
-17.6
PIPES
1.3
-15.7
7.8
-7.9
kanamycin B
HEPES
0.24
-13.1
4.2
-8.9
-18.8
PIPES
0.37
-15.7
7.1
-8.6
tobramycin
HEPES
0.22
-12.6
3.6
-9.0
-18.6
PIPES
0.32
-15.3
7.6
-8.7
sisomicin
HEPES
1.4
-16.9
9.0
-7.9
-21.5
PIPES
1.1
-19.0
11.0
-8.0
paromomycin I HEPES
1.9
-21.1
13.5
-7.6
-21.1
PIPES
2.9
-21.9
14.5
-7.4
neomycin B
HEPES
0.27
-15.4
6.5
-8.9
-19.8
PIPES
0.30
-17.4
8.7
-8.7
amikacin
HEPES
~40
NDc
ND
ND
-5.9
a
Determined at 293 K. Error values: KD, 3-15%, ΔH, 1-5%. The stoichiometry of
complex formation was 1.0 ± 0.2 for all titrations.
b
Intrinsic enthalpy change determined using equations 5a and 5b.
c
ND, not determined.
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disubstituted aminoglycosides tested, neomycin B and paramomycin I, the dissociation
constant also decreased in the presence of MgAMPCPP. This increase in affinity, in
contrast to the increase observed with the kanamycins, results from an increase in
favorable enthalpy of binding.
There is a correlation between the data from ITC experiments and previously
determined kinetic data (15) for the 4,6-disubstituted aminoglycosides. A decrease in Kd
values is observed with decreasing Km values. In the quaternary complex an increase in
−ΔH is observed with increasing kcat values.
Differences in the free energy of binding between structurally different
aminoglycosides and the enzyme showed the importance of several positions for affinity
and specificity. Four pairs of the aminoglycosides tested differed only by the substituent
at a single position. Comparison of the affinity within these sets of substrates was used to
determine the role of each position in determination of specifity.
Importance of the 1 position. The importance of position 1 on the deoxystreptamine
ring is evident by comparing the binding affinities of amikacin and kanamycin A. These
aminoglycosides are identical except that amikacin contains a 4-amino-2-hydroxybutyryl
(AHB) attachment on the amine at position 1 (Figure 1). The acylation of the amine at
position 1 results in an approximately twentyfold increase in the dissociation constant of
the binary complex and an approximately thirtyfold increase in the dissociation constant
in the quaternary complex. This may, however, contain additional contributions and may
cause overestimation of the position 1 because the size of the AHB group may allow it to
interfere with interactions with other positions on the aminoglycoside. The bulky AHB
group may also provide a steric hindrance to aminoglycoside binding.
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Importance of the 2′ position. The importance of this position for catalysis of the
modification of aminoglycosides by ANT(2″) has been demonstrated previously.(12, 15)
The importance of this position for binding to ANT(2″) is illustrated by comparing the
ITC-determined binding parameters of kanamycin A and kanamycin B (Tables 1 and 2,
Figure 2). These two aminoglycosides are identical with the exception of the substituent
at the 2′ position. Kanamycin A contains a 2′-OH while kanamycin B contains a 2′-NH2.
Kanamycin B has an approximately fivefold higher affinity for the enzyme in both the
binary and quaternary complexes. The thermodynamic basis for this difference in affinity
is different for the two complexes. In the binary complex the enthalpy of binding is about
5.5 kcal/mol more negative for kanamycin B than kanamycin A. This difference is
partially diminished by a more unfavorable (more negative) entropy for kanamycin B
resulting in an overall more favorable free energy of binding for kanamycin B compared
to kanamycin A. In the quaternary complex the difference in enthalpy is much smaller.
The intrinsic enthalpy of binding is only 1.2 kcal/mol more negative for kanamycin B and
the observed ΔH values are similar. However in the quaternary complex the entropy
(TΔS) is more negative for kanamycin A resulting in weaker binding for kanamycin A
compared to kanamycin B. The ability of an amino group to form more hydrogen bonds
than a hydroxyl group may explain the greater affinity for kanamycin B. Hydrogen bonds
are the major interactions governing affinity and specificity in enzyme–carbohydrate
interactions (21-23). The change from an amino to hydroxyl group can alter the number
and geometry of hydrogen bonds formed in the complex. This change can not only have a
direct effect, it can also alter the hydrogen-bonding network in the active site.
Alternatively, a positively charged 2′-amino group (pKa = 8.3 in free kanamycin B) (24)
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Figure 2: ITC profile of ANT(2″) in the presence of excess MgAMPCPP with
Kanamycin A(left) and Kanamycin B(right). Enzyme and ligand solutions contained 50
mM HEPES pH 7.5, 50 mM KCl and 2 mM TCEP. Identical ratios of titrant to protein
were used.
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may also be involved in electrostatic interactions with negatively charged side chains of
ANT(2″).
Importance of the 6′ position. Neomycin B and paromomycin are not substrates for
ANT(2″). These two compounds are competitive inhibitors of the enzyme with Ki values
of 7.0 ± 3.1 µM for neomycin and 78 ± 24 µM for paromomycin at pH 7.5. These two
4,5-disubstituted aminoglycosides differ only at the 6′ position. Neomycin B contains a
6′-amino while paromomycin I contains a 6′-hydroxyl. In the binary enzyme–
aminoglycoside complexes the dissociation constant is at least tenfold lower for
neomycin than paromomycin. In the quaternary complexes the dissociation constant is
sevenfold higher for paromomycin in HEPES and tenfold higher in PIPES at pH 7.5. In
both the binary and quaternary titrations paromomycin had more favorable observed
enthalpy of binding. The weaker binding is evident in Figure 3 which shows titration of
the two 4,5-disubstituted aminoglycosides. In both cases, though, paromomycin had more
disfavorable entropy of binding leading to lower affinity compared to neomycin. Again,
as discussed for kanamycin A and kanamycin B, the ability of the amino group to be
involved in more hydrogen bonds or in electrostatic interactions (pKa of the 6′-NH2 is 8.6
in free neomycin) (25) are possible reasons for the observed tighter binding of neomycin
to the enzyme compared to paromomycin. These findings clearly indicate that the 6′amino group is important for binding to ANT(2″).
Although a change in the substituent at the 1, 2′ or 6′ caused a significant change in
affinity, a change at the 3′ position did not effect binding. Kanamycin B and tobramycin
are identical except for the 3′ position. Kanamycin B contains a 3′-OH while tobramycin
has a 3′-H. The thermodynamic parameters of the binding of these two aminoglycoside
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Figure 3: ITC profile of ANT(2″) in the presence of excess MgAMPCPP with neomycin
B (left) and paromomycin I (right). Enzyme and ligand solutions contained 50 mM
PIPES pH 7.5, 50 mM KCl and 2 mM TCEP. Identical ratios of titrant to protein were
used. The experiments were performed under identical conditions.

111

antibiotics to ANT(2″) are very similar to each other in both the binary and quaternary
complexes. This suggest that the 3′ position does not play an important role in
determining specificity for ANT(2″)–aminoglycoside interactions.
Implications for substrate specificity. At both the 2′ and 6′ positions the presence of an
amine rather than a hydroxyl increases the affinity of the aminoglycoside for the enzyme.
At position 1, modification of the amine leads to a dramatic decrease in affinity. These
observations are similar to those made with two other AGMEs; the aminoglycoside
phosphotransferase(3′)-IIIa (APH(3′)) and the aminoglycoside acetyltransferase(6′)-Iy
(AAC(6′)), where the presence of an amino group in place of a hydroxyl at the 2′ or 6′
position increased the binding affinity of aminoglycosides to these enzymes. Similar
preference shown by ANT(2″) is unusual that it modifies a remote site from these
positions while APH(3′) and AAC(6′) modify sites on the ring (A) containing these two
positions. The results observed with ANT(2″) not only provide insight into the role of
these functional groups in determining substrate specificity of this enzyme, but they also
provide a rationale for the specificity for 4,6-disubstituted aminoglycosides as opposed to
4,5-disubstituted aminoglycosides when combined with studies determining the substrate
conformations of aminoglycoside antibiotics. Earlier studies showed that the A and B
rings of aminoglycoside antibiotics adopt similar conformations in the active sites of
different AGMEs including ANT(2″) (26, 27) which led to a hypothesis that these two
rings make the most important contacts with enzymes and RNA (28). Thermodynamic
parameters of enzyme–aminoglycoside complexes determined in this work lend further
support to this hypothesis and indicate that indeed several groups on the rings A and B of
aminoglycosides make the most important contacts with ANT(2″). Functional groups on
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rings A and B determine substrate specificity despite the fact that this enzyme modifies a
site on ring C. Figure 4 shows kanamycin A and neomycin B superimposed at the primed
and unprimed rings as described earlier.(27) The sites of interaction on these rings are
indicated by arrows. Thus, even though the site of modification for ANT(2″) is on ring C,
these interactions anchor these two rings in the active site. In the case of 4,6-disubstituted
aminoglycosides, this positions the hydroxyl at the 2″ position for nucleophilic attack on
the α-phosphate of ATP. For 4,5-disubstituted aminoglycosides, no hydroxyl is close
enough for interaction with ATP (Figure 4). A full rotation of the glycosidic bond
between the B and C rings will not bring any hydroxyls of neomycin B closer than 3.3 Å
to the 2″-OH of kanamycin A. Thus, this explains why neomycins can bind to ANT(2″)
competitively with substrates but are not modified by this enzyme.
There is no structural information available for ANT(2″). Therefore, assigning specific
interactions to the changes in enthalpy, entropy and free energy are not possible. Also,
any interpretation of changes in enthalpy and entropy due to the change in one substituent
on the aminoglycoside is complicated by the contribution of solvent, by enthalpy–entropy
compensation and by the effects of cooperative hydrogen bonding. However, the change
in free energy due to the change in a single substituent on the aminoglycoside does reveal
the molecular determinants of affinity and specificity for aminoglycoside binding to
ANT(2″). Understanding the contributions of specific functional groups to the free
energy of binding of different aminoglycoside antibiotics to this important resistance
enzyme will be useful in designing new antimicrobial agents less susceptible to
modification.
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Figure 4: Kanamycin A (red) and neomycin B (blue) from the crystal structure of
APH(3′)(29) superimposed as described in reference 27. The A and B rings superimpose
with enzyme-bound conformations determined by NMR spectroscopy with an RMSD of
less than 0.18 Å. Positions (1-, 2′- and 6′) determined in this study to be important for
aminoglycoside binding to ANT(2″) are indicated with green arrows. The site of
modification (2″-OH) on kanamycin A is shown as a red ball. The 2″-OH on neomycin B
is indicated with a blue ball.
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Part V. Effects of Mutation and Modification of Cysteine Residues
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Abstract

Stepwise removal of the cysteine residues in aminoglycoside nucleeotidyltransferse
(2″)-Ia by site-directed mutagenesis was done in an attempt to improve the folding
characteristics of this protein. Also the importance of the cysteine residues for folding
and activity were assessed. Six mutants of ANT(2″) containing five, four, three, two, one
and no cysteines were compared to the wild type enzyme. Removal of cysteines did not
increase the level of ANT(2″) found in the soluble fraction of cell lysate when the protein
was expressed in E. coli BL21(DE3). Circular dichroism spectra indicated that all
mutants had a similar fold to wild type. However, mutants lacking cysteine at position
136 had less than 10% of wild type activity. The use of reducing agents had only a minor
effect on wild type enzyme activity while the effect of sulfhydryl alkylating agents was
comparable to the effect of mutation of residue 136. These results suggest that C136 is
involved in substrate binding or catalysis rather than a disulfide bond.

Introduction

Aminoglycoside nucleotidyltransferase contains seven cysteine residues of 226 in the
amino acid sequence (Figure 1). In an attempt to improve the solubility and stability of
the protein for structural studies the cysteine residues were replaced with either alanine or
serine. The rationale for this approach is twofold. First, the aggregation of folded
ANT(2″) could be a result of the formation of intermolecular disulfide bonds. Second, the
initial folding of the enzyme in vivo may be slowed by the presence of cysteines. This
slow rate of folding coupled with overexpression of the protein could be the cause of
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3

6

27

MACYDCFFVQ SMPRASKQQA RTAVGRCLML WSSNDVTQQG SRPKTKLGRM
DTTQVTLIHK ILAAADERNL PLWIGGGWAI DARLGRVTRK HDDIDLTFPG
136

ERRGELEAIV EMLGGRVMEE LDYGFLAEIG DELLDCEPAW WADEAYEIAE
156

171

APQGSCPEAA EGVIAGRPVR CNSWEAIIWD YFYYADEVPP VDWPTKHIES
205

YRLACTSLGA EKVEVLRAAF RSRYAA
Figure 1: The amino acid sequence for ANT(2″)-Ia. Cysteine residues are underlined and
in bold type.
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inclusion body formation. Also the efficiency of folding from inclusion bodies could be
improved by removing cysteine residues. A more rapid rate of refolding could decrease
the incidence of aggregation caused by hydrophobic interaction between hydrophobic
portions of the protein which are buried in the native structure.
Also because the cellular location of aminoglycoside-modifying enzymes is still
controversial (1-3) the possibility of disulfide bonding has to be considered. Whether the
enzymes are present in the cytoplasm where the reducing environment would inhibit
disulfide formation or in the periplasmic space where disulfide formation can occur has
not been resolved. However because of the limited availability of ATP in the periplasmic
space ANT(2″) is probably located in the cytoplasm.
The mutations were done in a stepwise manner instead of individually because the
initial aim was to generate an active ANT(2″) removing all non-essential cysteines. The
first two cysteines (residues no.3 and 6) were changed to alanines creating an ANT(2″)
with only five cysteine residues. One by one each remaining cysteine was changed to a
serine residue. This process ultimately resulted in an ANT(2″) containing no cysteines.
The individual mutants and the nomenclature used to describe each are outlined in table
1.

Materials and Methods

Materials. All chemicals were of the highest purity commercially available. All
reagents were purchased from Sigma-Aldrich Co. (St. Louis, MO) except for inorganic
pyrophosphatase purchased from Roche Diagnostics Corp. (Indianapolis, IN),
dithiothreitol (DTT) and isopropylthiogalactopyranoside (IPTG) purchased from Inalco
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Table 1: Nomenclature used for the cysteine mutants discussed in this section
Name
Mutation
5 cys
C3A C6A
4 cys
C3A C6A C27S
3 cys
C3A C6A C27S C136S
2 cys
C3A C6A C27S C136S C156S
1 cys
C3A C6A C27S C136S C156S C171S
No cys
C3A C6A C27S C136S C156S C171S C205S
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Pharmaceuticals (Milan, Italy)and E. coli BL21(DE3) and pET 22b(+) purchased from
Novagen (Madison, WI).
Cloning and expression. The original cloning of ANT(2″) has been described
previously(4, 5). The original pET22b(+) vector engineered to produce ANT(2″) was
mutated to replace cysteine residues with either alanine or serine residues by Bio S&T,
Inc. (Montreal, Canada). These constructs were transformed into E. coli BL21(DE3). The
cells containing recombinant plasmid were selected on LB plates containing 100 mg/L
ampicillin. A single colony from each construct was grown 12 h in 10 mL of LB
containing 100 mg/L ampicillin. These cultures were then transferred to 1 L of LB
medium and grown to an OD600 of 0.4. After induction the cells were harvested as
described previously (5). All mutants of ANT(2″), similar to wild type, were found to
predominantly in the insoluble fraction of the cell lysate as inclusion bodies. The protein
for each mutation was isolated as described previously(5).
Enzyme activity assays. Activity assays for ANT(2″) were performed as described
previously. For determination of the concentration dependent inactivation of ANT(2″) by
iodoacetamide, N-ethylmaleimide (NEM) or dithiothreitol (DTT) the enzyme was
incubated for 30 min with either iodoacetamide, NEM or DTT at 30°C. The enzyme was
then kept on ice for 15 min prior to the start of the assay. For determination of kinetic
parameters for ANT(2″) with extensive alkylation of cysteine residues, 25 µM protein
was incubated with 50 mM iodoacetamide for 1 h under nitrogen at room temperature.
The enzyme was dialyzed 12 h against 50 mM HEPES pH 8.0 to remove excess
iodoacetamide.
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Circular dichroism spectroscopy. All circular dichroism (CD) spectra were collected
on an Aviv (Lakewood, NJ) model 202 spectrometer. All spectra were collected at 25°C.
The CD signal was monitored from 260 nm to 190 nm. All data represent the average of
five scans. The data was converted to percentage α-helix by CDNN CD spectra
deconvolution software version 2.0.

Results and Discussion

The mutants all expressed primarily as insoluble inclusion bodies (figure 2). After
refolding from inclusion bodies each mutant had comparable CD spectra. Deconvolution
of these spectra indicates that each mutant contained a similar percentage of α-helix
(table 2). The similar CD spectra suggest that all mutants have a overall structure. All
mutants, however, were not capable of enzymatic modification of aminoglycosides. The
5 cys and 4 cys mutants displayed activity similar to wild type enzyme. The 3 cys, 2 cys,
1 cys and no cys mutants all displayed less than 10% of wild type activity (figure 3).
From these results cysteine 136 is necessary for the activity of ANT(2″). There are two
possible reasons for the requirement of cysteine 136. First, this residue could be
necessary for a required disulfide bond. Second, this residue could directly be involved in
binding of substrates or catalysis. To test these two possibilities activity assays of the
wild type protein under reducing conditions to reduce any disulfides and under conditions
in which free cysteines would be alkylated were performed.
First ANT(2″) activity in the presence of increasing concentrations of the reducing
agent, DTT, was tested. Increasing the concentration of DTT from 0 to 5 mM caused an
initial decrease in activity (figure 4). However, increasing the concentration from 5 to
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WT

4 cys

3 cys

no cys

ANT(2″)

Figure 2: The majority of the protein expressed for all mutants and wild type is
recovered in the insoluble fraction of cell lysate. The soluble (sol) and insoluble (ins)
fractions were run on a 10% SDS-PAGE after separation by centrifugation for 15 min at
12,000 × g.
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Table 2: Percentage α-helix in wild type and mutant ANT(2″) as determined by
circular dichroism
Percentage α-helixa
Wild Type
38
5 cys
34
4 cys
41
3 cys
40
2 cys
33
1 cys
42
No cys
38
a
Determined as described in materials and methods. The standard error is ± 10%.
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Figure 3: The activity of cysteine mutants determined at pH 8.0. Each assay contained
1.0 mM MgATP and 40µM tobramycin.
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Figure 4: The activity of wild type ANT(2″) after incubation with indicated
concentration of DTT for 30 min at 30°C. Activity determined at pH 8.0. Each assay
contained 1.0 mM MgATP and 40µM tobramycin. DTT was added to assay mixture to
maintain concentration at indicated levels.
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100 mM caused no further loss of activity. These results lead to the conclusion that the
loss in activity in the 3 cys mutant is not due to the inability to form an essential
disulfide bond. If that were the case, the loss of activity under extreme reducing
conditions (100 mM) would be comparable to the loss of activity in the 3 cys mutant. To
eliminate the unlikely possibility of the existence of a buried disulfide inaccessible t
o reducing agent the protein was refolded in 100 mM DTT after denaturation with 8 M
urea. This refolded protein retained 75% of activity compared to standard assay
conditions (1 mM DTT). This result compared favorably with the results shown in figure
4 in which the addition of 100 mM DTT to folded protein led to approximately 80% of
normal activity. These results provide more evidence that the loss of activity in the 3 cys
mutant is not a consequence of the loss of an essential disulfide bond.
To test whether the loss of activity in the 3 cys mutant results from involvement of a
cysteine residue in substrate binding or catalysis two sulfhydryl-modifying reagents were
employed, iodoacetamide and NEM. First alkylation of cysteine residues was performed
by incubation with a large excess (>250-fold) of iodoacetamide followed by removal of
unreacted iodoacetamide by dialysis. This process reduced activity (Vmax) from 0.18
units/mg to less than 0.01 units/mg. Because iodoacetamide at very high concentrations
can modify other residues the concentration dependence was investigated. The loss in
activity due to alkylation by iodoacetamide was found to be concentration dependent with
a 50% reduction at approximately 5 mM iodoacetamide (figure 5, top). Another
alkylating agent, NEM, also inactivated ANT(2″) in a concentration dependent manner
(figure 5, bottom). Finally to determine the role of cysteine in ANT(2″) catalysis,
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Figure 5: The activity of wild type ANT(2″) after incubation with indicated
concentration of iodoacetamide (top) or N-ethylmaleimide (bottom) for 30 min at 30°C.
Activity determined at pH 8.0. Each assay contained 1.0 mM MgATP and 40µM
tobramycin.
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the substrates were tested for the ability to protect against inactivation by iodoacetamide.
Preincubating the enzyme with increasing concentrations of Mg2+ had no effect on the
inactivation by iodoacetamide. Preincubation with increasing concentrations of MgATP,
however, did protect against inactivation by iodoacetamide (Figure 6). Data from
protection assays preincubation with aminoglycosides was not possible to interpret
because of substrate inhibition at aminoglycoside concentrations necessary for the
experiment. This data suggest that cysteine 136 is located in the MgATP binding site.
However binding of MgATP may cause a conformational change in the enzyme which
could also explain the protection against inactivation.

Conclusions

Although this data indicates that C136 is important for MgATP binding further work
is necessary to confirm the role of this residue. Binding experiments using wild type
ANT(2″) and the cysteine mutants need to be performed. Isothermal titration calorimetry
experiments to study binding of MgATP and aminoglycosides need to be undertaken to
directly determine the effect of the mutations. Also electron paramagnetic resonance to
observe metal binding and change in fluorescence to observe ATP binding should also be
completed. If binding of all substrates and cofactors is diminished in the inactive mutants
then the global fold of the enzyme is probably defective. If a single binding event is
affected in the inactive mutant the role of C136 can be explained.
If it is determined that the no cys mutant is capable of some functions (e.g.
aminoglycoside binding) then more detailed work will be necessary such as 15N-HSQC
NMR experiments to determine if it has similar structural properties to wild type
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Figure 6: The activity of wild type ANT(2″) after incubation with indicated
concentration of MgATP for 5 min followed by 20 min with 5 mM iodoacetamide at
30°C. Activity determined at pH 8.0. Each assay contained 1.0 mM MgATP and 40µM
tobramycin.
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ANT(2″). If the no cys mutant has improved solubility and stability it may be a better
candidate for structure determination than wild type ANT(2″). Also the solubility and
stability of the 4 cys mutant should be determined relative to wild type ANT(2″). This
mutant removes the most cysteines while retaining activity. This mutant may also be a
better option than wild type for structural studies. Finally if removal of cysteines does
improve solubility and stability one should consider reintroducing C136 into the no cys
mutant. The resulting mutant may have improved properties for structure determination
while retaining enzymatic activity.
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Overview

Previous work with ANT(2″) included determination of the resistance profile,
monitoring the frequency and spread of this enzyme, kinetic characterization with impure
or not well-defined forms of the enzyme and an enzyme-bound substrate conformation
using isepamicin. We have developed an isolation technique to obtain enzyme with a
high level of purity. This has led to the first kinetic studies with a well-defined form of
the enzyme and the first thermodynamic characterization of ANT(2″). The work
presented in this thesis should form a basis for future thermodynamic and structural
studies to better understand the interactions between ANT(2″) and aminoglycoside
antibiotics.

Future Work

The next stage of this project should consist of further thermodynamic
characterization of this enzyme using ITC and development of a method to increase the
solubility of ANT(2″) so that structural and dynamic studies are feasible. ITC has proven
to be a reliable technique to obtain thermodynamic data with ANT(2″). Further
characterization of interactions with aminoglycosides should include studies of binding as
a function of pH, temperature, ionic strength and osmotic stress.
Binding as a function of pH can be used not only to determine the pH optimum for
binding, but also can be used to determine any changes in pKa’s of important ionizable
groups upon binding (1-4). The change in binding enthalpy as a function of temperature
can be used to determine the heat capacity change (ΔCp) due to binding of ligand. This
change in heat capacity is thought to originate primarily from the change in solvent
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accessible surface area (5) . Binding as a function of ionic strength can be used to
determine the importance of ionic interactions. The number of groups participating in
ionic interactions can also be estimated using this method (6). Finally binding affinity as
a function of osmolality can be used to evaluate the role of water in binding interactions
by determining the net uptake or elease of water (7, 8).
For many of the experimental methods necessary for characterization of this enzyme
the concentration of enzyme needs to be greater. Characterization of this enzyme should
include structure determination by X-ray crystallography or NMR. Another goal of this
project is to study the dynamics of ANT(2″) by NMR. Both of these aims will require a
higher protein concentration than is currently obtainable. Also the protein is relatively
unstable and begins to lose activity after 60 h at 4°C and even more quickly at higher
temperatures. Two approaches should be considered to improve these properties.
First the buffer which provides maximum stability and solubility should be determined
in a quantitative manner. A screening technique similar to the one employed for
determination of the optimal refolding buffer should be used to find the best storage
buffer. Variables such as pH, salt composition and concentration and reducing agent
composition and concentration should be tested. Additionally agents known to increase
protein stability such as sugars and alcohols should also be tested.
Another approach is to find conditions to produce soluble protein in vivo rather than
isolating ANT(2″) from inclusion bodies. Several cell lines designed to control
expression were tested, induction using different levels of IPTG (0-1 mM w/v), and
expression at different temperatures (10-30°C). These conditions altered the level of total
protein but did not change the ratio of insoluble to soluble protein recovered from the cell
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lysate. The expression vector, pET22b(+), has not been changed. Cloning the gene for
ANT(2″)-Ia into other expression vectors should be explored. Expression vectors which
produce the protein of interest as a fusion protein with maltose-binding protein should be
tested. This method has been shown to increase production of soluble protein in some
cases (9, 10).

Implications for Combatting Antibiotic Resistance

The results from kinetic and thermodynamic studies show that the functional groups at
the 1, 2′ and 6′ positions are important for aminoglycoside binding to ANT(2″). These
three positions are also important for binding to the other two aminoglycoside-modifying
enzymes that have thermodynamic data available, AAC(6′)-Iy and APH(3′)-IIIa (11, 12).
This information in addition to the previous observation that the A and B rings of
aminoglycosides adopt the same conformation in the active site of different
aminoglycoside-modifying enzymes suggest a common recognition motif for
aminoglycoside binding (13). The structural and thermodynamic aspects of rRNA–
aminoglycoside interactions have been described extensively (14-20). Rings A and B of
aminoglycosides adopt a similar conformation bound to either RNA or AGMEs.
Positions 2′ and 6′ also make important contacts with RNA. Therefore generating new
aminoglycosides lacking the functional groups necessary for tight binding to resistance
enzymes will not be effective antibiotics (21). Another option to combat resistance due to
ANT(2″) is modification of the 1 position. However, the introduction of amikacin, which
has an alkyl group attached to position 1 has led to the emergence of resistance enzymes
which modify this aminoglycoside (22). So the introduction of semi-synthetic
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aminoglycosides which are not modified by the more prevalent resistance enzymes is an
ineffective long-term strategy for preventing AGME-mediated resistance. The best
strategy may be to produce inhibitors of aminoglycoside antibiotics to be co-administered
with aminoglycosides or to develop novel antibiotics based on the mode of action of
aminoglycosides but lacking the aminoglycoside framework. The first non-carbohydrate
inhibitor of ANT(2″) competitive with the aminoglycoside substrate has already been
produced using this strategy (23). The information from aminoglycoside interactions with
ANT(2″) as well as thermodynamic and structural information from other
aminoglycoside-modifying enzymes can be used to design inhibitors effective against
different classes of AGMEs or to design new antibiotics that bind to bacterial rRNA and
disrupt translation but are not susceptible to resistance enzymes.
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